Evaluation of volumetric modulated arc therapy (VMAT) patient specific quality assurance by Mancuso, Gordon Mark
Louisiana State University
LSU Digital Commons
LSU Master's Theses Graduate School
2011
Evaluation of volumetric modulated arc therapy
(VMAT) patient specific quality assurance
Gordon Mark Mancuso
Louisiana State University and Agricultural and Mechanical College
Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_theses
Part of the Physical Sciences and Mathematics Commons
This Thesis is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU
Master's Theses by an authorized graduate school editor of LSU Digital Commons. For more information, please contact gradetd@lsu.edu.
Recommended Citation
Mancuso, Gordon Mark, "Evaluation of volumetric modulated arc therapy (VMAT) patient specific quality assurance" (2011). LSU
Master's Theses. 706.
https://digitalcommons.lsu.edu/gradschool_theses/706
EVALUATION OF
VOLUMETRIC MODULATED ARC THERAPY (VMAT) PATIENT
SPECIFIC QUALITY ASSURANCE
A Thesis
Submitted to the Graduate Faculty of the
Louisiana State University and
Agricultural and Mechanical College
in partial fulfillment of the
requirements for the degree of
Master of Science
in
The Department of Physics and Astronomy
by
Gordon Mark Mancuso
B.S., Brigham Young University, 2008
May 2011
Acknowledgements
I am deeply indebted to a large number of people for supporting me during my academic
career. This thesis work would not have been possible without my advisor, Dr. Jonas
Fontenot, who has constantly been a source of guidance as he has assisted me in its
completion. I’d like to thank my supervisory committee, consisting of the following people:
Dr. John Gibbons, Dr. Gabriela Gonza´lez, Daniel Neck, and Dr. Brent Parker. I appreciate
all of their comments, feedback, and encouragement, and for taking time from their busy
schedules to meet with and assist me in this work.
I also would like to extend thanks to all of those who have guided and instructed me as
part of my graduate experience, including Dr. Kenneth Matthews, Dr. Polad Shikhaliev, Dr.
Wei-Hsung Wang, and Dr. Erno Sajo at LSU, and all of the faculty, staff, and physicians
at Mary Bird Perkins Cancer Center. Without these people, I would not know about
scintillation detectors, the Radon transform, the number of rems in a sievert, nor which
flagon has the brew that is true. I especially want to thank Dr. Kenneth Hogstrom, whose
dedication to this program, teaching, and to the advancement of medical physics has been
a source of inspiration throughout my graduate career. I am also thankful to my fellow
graduate students. We’ve been through a lot together, and I am sure some of us will have
opportunities to work together in the future. I look forward to it.
Louisiana State University and Mary Bird Perkins Cancer Center deserve special thanks
for supporting me both financially and with such excellent facilities in which to learn. In
addition, I extend thanks to Elekta, Inc. for their part in sponsoring this research.
I’d like to thank Page Barcia, Susan Hammond, and Yvonne Thomas for all of their
assistance and support throughout my graduate career. The medical physics program and
the physics department at Mary Bird would have a difficult time functioning without their
efforts and dedication.
ii
My parents, Mark and Tammy Mancuso, have been a constant support to me throughout
my life. As I grow older, I realize more and more how much they sacrificed to provide me
with all the opportunities I have had. I thank them for always loving me and teaching me
to stay on the right path, and for gently guiding me back when I’ve erred.
Finally, I am eternally grateful to my beautiful wife Megan, on whom I’ve come to rely
more and more as time has passed. I am so very blessed to have her, and I am so thankful
for her patience with me. I would be a lonely, sad, and hungry man without her.
iii
Table of Contents
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ii
List of Tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vi
List of Figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . viii
Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xii
Chapter 1: Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1 VMAT Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.1 History of VMAT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.2 VMAT Advantages and Disadvantages . . . . . . . . . . . . . . . . . 6
1.2 IMRT Patient Specific QA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.2.1 IMRT Point Dose Analysis . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.2.2 IMRT Planar Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.2.3 AAPM Task Group 119 . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
1.3 Motivation for Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
1.4 Hypothesis and Specific Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
1.4.1 Specific Aim 1: Develop IMRT and VMAT Plans for TG 119 Structures
That Meet Specified Dose Objectives . . . . . . . . . . . . . . . . . . . 19
1.4.2 Specific Aim 2: Deliver Planned Treatments to a Cylindrical Phantom
and to a 2D Diode Array . . . . . . . . . . . . . . . . . . . . . . . . . . 19
1.4.3 Specific Aim 3: Analyze the Collected Data and Test for Significance 19
Chapter 2: Methods and Materials . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.1 Experimental Geometry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.2 Treatment Planning . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.2.1 Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.2.2 Planning Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.2.3 Initial Setup . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.2.4 General Optimization . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.2.5 Plan Specific Optimization . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.2.6 Evaluation of the Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.2.7 Data Export . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
2.3 Experimental Measurements . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.3.1 Measurement Materials . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.3.2 Point and Planar Dose Calibration . . . . . . . . . . . . . . . . . . . . 39
2.3.3 Point and Planar Dose Measurements . . . . . . . . . . . . . . . . . . 41
2.3.4 MapCHECK Measurements . . . . . . . . . . . . . . . . . . . . . . . . 43
2.4 Data Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
2.4.1 Point Dose Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
iv
2.4.2 Film Scanning . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
2.4.3 Film Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
2.4.4 MapCHECK Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
2.4.5 Statistical Tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
Chapter 3: Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.1 Planning Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.2 Point Dose Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.3 Film Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.4 MapCHECK Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
3.5 Data Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
Chapter 4: Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
4.1 Comparison to Previous Work . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
4.2 Possible Limitations of the Work . . . . . . . . . . . . . . . . . . . . . . . . . 83
4.2.1 Normality . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
4.3 Further Work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
Chapter 5: Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
Appendix A: Film Images . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
Appendix B: MapCHECK Images . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Vita . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
v
List of Tables
1.1 TG 119 results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
2.1 Dose goals for the TG 119 structures . . . . . . . . . . . . . . . . . . . . . . . 22
2.2 Beam setup overview for each plan . . . . . . . . . . . . . . . . . . . . . . . . 25
2.3 Optimization settings for IMRT plans . . . . . . . . . . . . . . . . . . . . . . 26
2.4 Optimization settings for VMAT plans . . . . . . . . . . . . . . . . . . . . . . 27
2.5 Optimization parameters for the multitarget plans . . . . . . . . . . . . . . . 28
2.6 Optimization parameters for the prostate IMRT plan . . . . . . . . . . . . . . 29
2.7 Optimization parameters for the head and neck plans . . . . . . . . . . . . . 30
2.8 Optimization parameters for the C-shape plans . . . . . . . . . . . . . . . . . 32
2.9 Point dose calculation and measurement locations . . . . . . . . . . . . . . . 33
2.10 Settings used for exporting planar dose files . . . . . . . . . . . . . . . . . . . 34
2.11 Crop dimensions used in RIT before IMRT analysis . . . . . . . . . . . . . . 50
3.1 Treatment planning results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
3.2 Point dose measurements: Dose . . . . . . . . . . . . . . . . . . . . . . . . . . 60
3.3 Point dose measurements: Percent difference . . . . . . . . . . . . . . . . . . 61
3.4 Point dose measurements aggregated by point . . . . . . . . . . . . . . . . . 62
3.5 Point dose measurements aggregated by modality . . . . . . . . . . . . . . . 63
3.6 Film gamma calculation results . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.7 Film gamma results aggregated by treatment setup . . . . . . . . . . . . . . . 64
3.8 Film gamma results aggregated by modality . . . . . . . . . . . . . . . . . . 69
3.9 MapCHECK gamma calculation results . . . . . . . . . . . . . . . . . . . . . 69
3.10 MapCHECK gamma results aggregated by treatment . . . . . . . . . . . . . 70
3.11 MapCHECK gamma results aggregated by modality . . . . . . . . . . . . . . 70
4.1 Individual institution point dose results from TG 119 . . . . . . . . . . . . . 82
vi
4.2 Individual institution composite film results from TG 119 . . . . . . . . . . . 83
4.3 Site-specific normality check: Data transformation . . . . . . . . . . . . . . . 86
vii
List of Figures
1.1 Increasing conformity to the target volume . . . . . . . . . . . . . . . . . . . 2
1.2 Example of how an IMRT treatment can conform to a concave target shape . 3
1.3 Methods of using MLCs to create intensity distributions . . . . . . . . . . . . 4
1.4 The composite delivery method for patient specific IMRT QA . . . . . . . . 8
1.5 The field-by-field delivery method for patient specific IMRT QA . . . . . . . 9
1.6 Sample percent dose difference profile comparison . . . . . . . . . . . . . . . 11
1.7 The distance to agreement method . . . . . . . . . . . . . . . . . . . . . . . . 11
1.8 Sample DTA profile comparison . . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.9 Sample binary DTA and dose difference composite comparison . . . . . . . 13
1.10 Two sets of profiles with 100% of points passing the binary composite test . 14
1.11 Sample gamma analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.1 The four structure sets given to the AAPM 119 institutions . . . . . . . . . . 20
2.2 CT image of a slice of the cylindrical phantom . . . . . . . . . . . . . . . . . 24
2.3 Tabular DVH example . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.4 Prescription dose window . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.5 Elekta Infinity linear accelerator . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.6 Cylindrical “cheese” phantom . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.7 Cylindrical phantom separated into semicylinders . . . . . . . . . . . . . . . 36
2.8 Exradin A1SL ion chamber . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.9 Keithley 614 electrometer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
2.10 EBT2 film . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
2.11 MapCHECK device and MapPHAN phantom . . . . . . . . . . . . . . . . . 39
2.12 Calibration film . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
2.13 EBT2 film in place on the cylindrical phantom . . . . . . . . . . . . . . . . . 43
viii
2.14 Vidar DosimetryPro Advantage scanner . . . . . . . . . . . . . . . . . . . . . 46
2.15 Horizontal profile of EBT2 film scanned on the red Vidar scanner . . . . . . 47
2.16 Horizontal profile of EBT2 film scanned on the white Vidar scanner . . . . . 47
2.17 Cross section of EBT2 film . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
2.18 Comparison of RIT and in-house gamma analysis results . . . . . . . . . . . 51
2.19 Batch analysis window in the MapCHECK software . . . . . . . . . . . . . . 52
2.20 Sample comparison report from MapCHECK results . . . . . . . . . . . . . . 54
3.1 Multitarget IMRT isodose distribution and DVH . . . . . . . . . . . . . . . . 56
3.2 Multitarget VMAT isodose distribution and DVH . . . . . . . . . . . . . . . 58
3.3 Prostate IMRT isodose distribution and DVH . . . . . . . . . . . . . . . . . . 58
3.4 Prostate VMAT isodose distribution and DVH . . . . . . . . . . . . . . . . . 58
3.5 Head and neck IMRT isodose distribution and DVH . . . . . . . . . . . . . . 59
3.6 Head and neck VMAT isodose distribution and DVH . . . . . . . . . . . . . 59
3.7 C-shape IMRT isodose distribution and DVH . . . . . . . . . . . . . . . . . . 59
3.8 C-shape VMAT isodose distribution and DVH . . . . . . . . . . . . . . . . . 60
3.9 Representative gamma results for the multitarget film data. . . . . . . . . . . 65
3.10 Representative gamma results for the prostate film data. . . . . . . . . . . . 66
3.11 Representative gamma results for the head and neck film data. . . . . . . . . 67
3.12 Representative gamma results for the C-shape film data. . . . . . . . . . . . 68
3.13 Representative MapCHECK output for a multitarget IMRT delivery . . . . . 71
3.14 Representative MapCHECK output for a multitarget VMAT delivery . . . . 72
3.15 Representative MapCHECK output for a prostate IMRT delivery . . . . . . . 73
3.16 Representative MapCHECK output for a prostate VMAT delivery . . . . . . 74
3.17 Representative MapCHECK output for a head and neck IMRT delivery . . . 75
3.18 Representative MapCHECK output for a head and neck VMAT delivery . . 76
3.19 Representative MapCHECK output for a C-shape IMRT delivery . . . . . . 77
3.20 Representative MapCHECK output for a C-shape VMAT delivery . . . . . . 78
ix
4.1 Vertical film profiles displaying a systematic shift . . . . . . . . . . . . . . . 85
4.2 Normality histograms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
A.1 Second set of gamma results for the multitarget film data. . . . . . . . . . . . 95
A.2 Second set of gamma results for the prostate film data. . . . . . . . . . . . . . 96
A.3 Second set of gamma results for the head and neck film data. . . . . . . . . . 97
A.4 Second set of gamma results for the C-shape film data. . . . . . . . . . . . . 98
A.5 Third set of gamma results for the multitarget film data. . . . . . . . . . . . . 99
A.6 Third set of gamma results for the prostate film data. . . . . . . . . . . . . . 100
A.7 Third set of gamma results for the head and neck film data. . . . . . . . . . . 101
A.8 Third set of gamma results for the C-shape film data. . . . . . . . . . . . . . 102
B.1 Second MapCHECK result for the multitarget IMRT delivery . . . . . . . . . 104
B.2 Second MapCHECK result for the multitarget VMAT delivery . . . . . . . . 105
B.3 Second MapCHECK result for the prostate IMRT delivery . . . . . . . . . . . 106
B.4 Second MapCHECK result for the prostate VMAT delivery . . . . . . . . . . 107
B.5 Second MapCHECK result for the head and neck IMRT delivery . . . . . . . 108
B.6 Second MapCHECK result for the head and neck VMAT delivery . . . . . . 109
B.7 Second MapCHECK result for the C-shape IMRT delivery . . . . . . . . . . 110
B.8 Second MapCHECK result for the C-shape VMAT delivery . . . . . . . . . . 111
B.9 Third MapCHECK result for the multitarget IMRT delivery . . . . . . . . . . 112
B.10 Third MapCHECK result for the multitarget VMAT delivery . . . . . . . . . 113
B.11 Third MapCHECK result for the prostate IMRT delivery . . . . . . . . . . . 114
B.12 Third MapCHECK result for the prostate VMAT delivery . . . . . . . . . . . 115
B.13 Third MapCHECK result for the head and neck IMRT delivery . . . . . . . . 116
B.14 Third MapCHECK result for the head and neck VMAT delivery . . . . . . . 117
B.15 Third MapCHECK result for the C-shape IMRT delivery . . . . . . . . . . . 118
B.16 Third MapCHECK result for the C-shape VMAT delivery . . . . . . . . . . . 119
B.17 Fourth MapCHECK result for the multitarget IMRT delivery . . . . . . . . . 120
x
B.18 Fourth MapCHECK result for the multitarget VMAT delivery . . . . . . . . 121
B.19 Fourth MapCHECK result for the prostate IMRT delivery . . . . . . . . . . . 122
B.20 Fourth MapCHECK result for the prostate VMAT delivery . . . . . . . . . . 123
B.21 Fourth MapCHECK result for the head and neck IMRT delivery . . . . . . . 124
B.22 Fourth MapCHECK result for the head and neck VMAT delivery . . . . . . 125
B.23 Fourth MapCHECK result for the C-shape IMRT delivery . . . . . . . . . . . 126
B.24 Fourth MapCHECK result for the C-shape VMAT delivery . . . . . . . . . . 127
B.25 Fifth MapCHECK result for the multitarget IMRT delivery . . . . . . . . . . 128
B.26 Fifth MapCHECK result for the multitarget VMAT delivery . . . . . . . . . . 129
B.27 Fifth MapCHECK result for the prostate IMRT delivery . . . . . . . . . . . . 130
B.28 Fifth MapCHECK result for the prostate VMAT delivery . . . . . . . . . . . 131
B.29 Fifth MapCHECK result for the head and neck IMRT delivery . . . . . . . . 132
B.30 Fifth MapCHECK result for the head and neck VMAT delivery . . . . . . . . 133
B.31 Fifth MapCHECK result for the C-shape IMRT delivery . . . . . . . . . . . . 134
B.32 Fifth MapCHECK result for the C-shape VMAT delivery . . . . . . . . . . . 135
xi
Abstract
Purpose: The purpose of this work was to perform a comprehensive comparison of
fixed-beam intensity modulated radiation therapy (IMRT) and volumetric modulated arc
therapy (VMAT) patient specific quality assurance (QA) results, in order to investigate
the appropriateness of applying IMRT QA methods and action levels to VMAT treatment
plans.
Methods: QA measurements were evaluated for the test geometries provided in AAPM
Task Group Report 119. The structure sets were copied onto a cylindrical water-equivalent
phantom. Using the Philips Pinnacle3 treatment planning system, fixed-beam IMRT and
VMAT treatment plans were constructed. The plans were delivered to the phantom and
the resulting dose distributions were measured (1) in the coronal and sagittal planes and
at high and low dose points in the cylindrical phantom using radiochromic film and
ion chamber, respectively, and (2) using a commercial 2D diode array. Ion chamber and
diode array measurements were taken five times each, and film measurements were taken
three times. Measured planar doses were analyzed using gamma analysis with criteria
of 3%/3 mm. Measured point doses were analyzed using percent difference. Differences
between IMRT QA and VMAT QA results were tested for significance using the Wilcoxon
rank-sum test.
Results: The radiochromic film results showed averages of 98.9%±1.0% and 99.1%±0.9%
of measured doses within 3%/3 mm of calculated doses for IMRT and VMAT plans,
respectively. Ion chamber results showed average differences between measured and
calculated point doses of −0.7% ± 1.5% and −1.7% ± 1.8% for IMRT and VMAT plans,
respectively. The diode array results showed averages of 98.7% ± 0.5% and 98.6% ± 0.8%
of measured doses within 3%/3 mm of calculated doses for IMRT and VMAT plans,
respectively. The Wilcoxon rank-sum test found p values of p = 1.00, p = 0.27, and p = 0.89
for the film, point dose, and diode array measurements, respectively.
xii
Conclusion: Differences between IMRT QA and VMAT QA results were not statistically
significant for any of the measurement types. The measured differences between IMRT and
VMAT QA results were small and likely do not constitute clinically significant differences.
These results suggest that it is appropriate to apply IMRT QA methods and action levels to
VMAT treatments.
xiii
Chapter 1
Introduction
1.1 VMAT Overview
1.1.1 History of VMAT
IMRT
The primary goal of radiation therapy is to deliver a prescribed dose to a target volume,
while minimizing the deleterious effects of radiation to normal tissue (Khan 2010). This
is referred to as conforming the dose to the target. Various techniques are employed to
achieve this goal. For example, multiple beams may enter the patient from different angles,
all irradiating the target volume. The summing of doses at the focus point allows a high
dose to be delivered there while comparatively lower doses are delivered to surrounding
normal tissue. Another technique employed is to choose beam angles that avoid critical
structures, thus reducing the dose to organs of comparatively low radiation tolerance.
A technique called intensity modulated radiation therapy (IMRT) is a method employed
to further reduce dose to critical structures while maintaining a high uniform dose to
a target volume. IMRT is distinguished from conventional radiotherapy by the ability
to deliver fields of nonuniform intensity (Webb 2003). While wedges may be used in
conventional therapy to achieve nonuniform intensity, wedges are inherently unidirectional
and inflexible. IMRT, on the other hand, is much more adaptable. Figure 1.1 illustrates
increasing conformity to the target. For much of the history of radiation therapy, treatment
fields were limited to rectangular fields, with the addition of blocks and wedges. In
Fig. 1.1(a), the rectangular field covers the dashed outline of the target, but also irradiates
surrounding tissue due to the irregular shape of the target. While blocks can be used to
reduce this effect, they are time consuming to construct, and changes to the treatment plan
may require new blocks to be made. When multileaf collimators (MLCs) became available,
1
(a) (b)
(c)
Figure 1.1: Increasing conformity to the target volume. (a) Treatment with rectangular
fields was the treatment method used for almost a century, with the addition of wedges
and blocks. (b) This illustrates 3D conformal radiotherapy, in which multileaf collimators
make it easier to conform fields to the outline of a target. (c) IMRT allows the intensity to
vary at different points in the field. Figure adapted from Webb (2003).
it became significantly easier to conform the radiation to the target shape (see Fig. 1.1(b)).
This is typically referred to as 3D conformal radiotherapy (3DCRT). However, while MLCs
shape the beam to follow the outline of the target, the beam is still of uniform intensity
across the entire area being irradiated. Figure 1.1(c) illustrates the concept of utilizing
varying intensities in each bixel in the radiation field, which is the primary distinction of
IMRT. Different areas can receive differing amount of radiation from a single gantry angle.
By adding up several of these fields from different angles, the composite dose distribution
can yield a high uniform dose to the target while reducing the dose to the surrounding
normal tissue.
IMRT offers a significant advantage over 3DCRT. A single beam using 3DCRT only
conforms to the target in two dimensions, and 3DCRT cannot create a concave dose
2
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(a) (b)
Figure 1.2: Example of how an IMRT treatment can conform to a concave target shape.
Shown are (a) a 3DCRT treatment and (b) an IMRT treatment. The prostate is the target,
and the rectum and bladder are organs at risk. A representative PTV isodose line is shown
in red for each figure. 3DCRT delivers a uniform intensity over the field, and cannot create
a concave dose distribution. IMRT can vary the intensity across the field, and thus provide
better sparing of the organs in the concave regions. Figure adapted from Webb (2003).
distribution. As a result, planning target volumes (PTVs) with concave shapes, like the
prostate shown in Fig. 1.2(a), will result in normal tissue in the concave areas being
unnecessarily irradiated when treated with 3DCRT. IMRT, on the other hand, reduces the
level of this unnecessary radiation, which is especially useful when organs at risk (OARs)
lie in the concave regions. By decreasing the amount of radiation traveling through an
OAR, the dose to the organ can be reduced without compromising the uniform dose to
the target (see Fig. 1.2(b)). The use of IMRT has repeatedly been shown to reduce dose to
OARs compared with 3DCRT (Arbea et al. 2010; Zabel et al. 2002).
Intensity modulation can be achieved in a number of ways. These include compen-
sator based IMRT (Chang et al. 2004), helical slice-by-slice delivery (Mackie et al. 1993),
and selective fluence modulation using an MLC. The last of these techniques can be
achieved using two methods: “step-and-shoot” IMRT (SMLC-IMRT) and “dynamic” IMRT
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Step-and-shoot IMRT
Dynamic IMRT
Figure 1.3: Methods of using MLCs to create intensity distributions. When the
step-and-shoot method is used, the beam is off during leaf motion, while the dynamic
method delivers radiation during leaf motion. Figure from Bortfeld et al. (1999).
(DMLC-IMRT). A graphical representation of these two methods is shown in Fig. 1.3. In
step-and-shoot IMRT, the MLC leaves remain fixed during irradiation and the beam is
turned off between consecutive MLC shapes. Several small static fields are added up to
create the dose distribution. In dynamic IMRT, the leaves are in continuous motion while
the beam is on, moving in and out of the field to create the desired dose distribution. It
should be noted that the term “intensity modulation” is somewhat of a misnomer, as what
is really being modulated is the fluence. However, the term “intensity modulation” has
gained such widespread use that it is generally regarded as the proper method of referring
to the technique.
VMAT
Volumetric modulated arc therapy (VMAT) is a method of delivering intensity mod-
ulated fields that is currently gaining widespread use. VMAT is distinguished from
traditional fixed-beam IMRT in that the radiation is delivered while the gantry rotates
around the patient. The dose is shaped using three variables: MLC shape, gantry rotation
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speed, and dose rate. The primary advantage of VMAT over fixed-beam IMRT is that
VMAT treatments can be delivered significantly faster.
VMAT evolved from intensity modulated arc therapy (IMAT), which was first proposed
by Yu (1995). IMAT is similar to VMAT in that radiation is delivered while the gantry
rotates around the patient. With IMAT, however, the dose rate and gantry speed are held
constant. Intensity modulation is achieved by delivering radiation over multiple gantry
arcs. This means that the number of intensity levels is equal to the number of gantry arcs.
Increasing dose level resolution requires an increased number of arcs, which significantly
increases treatment time. Yu found that IMAT treatments took as long or longer to deliver
than comparable fixed-beam IMRT treatments. Yu observed that IMAT treatments spread
normal tissue dose around the patient, while fixed-beam IMRT treatments concentrate the
normal tissue dose along fixed lines.
Over the next decade, development of IMAT continued (Earl et al. 2003; Ma et al. 2001;
Ramsey et al. 2001; Wong, Chen, and Greenland 2002; Yu et al. 2002), but the modality did
not gain widespread clinical use. There were several reasons for this. First, there were no
commercially available tools for routine treatment planning (Shepard et al. 2007). Second,
the marginal dosimetric and delivery benefits of IMAT did not provoke much interest in
furthering its development.
In 2007, Shepherd et al. showed that treatment planning with IMAT gave better results in
fewer arc rotations when the gantry speed and dose rate were allowed to vary (Shepard et al.
2007). In 2008, Otto introduced the concept of volumetric modulated arc therapy, which
was originally described as delivering the radiation dose in a single 360◦ arc (Otto 2008).
This meant that treatments could be delivered significantly faster than with other IMRT
options. At this point, there were sufficient incentives for rapid clinical and commercial
development of VMAT tools and technology.
On Varian machines, VMAT is referred to as RapidArc, while on Elekta machines it is
simply called VMAT.
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1.1.2 VMAT Advantages and Disadvantages
VMAT has several potential advantages over traditional methods of IMRT delivery.
The main advantage is that treatments are delivered in a fraction of the time as compared
with fixed-beam IMRT treatments. Rao et al. (2010) compared VMAT treatments with
fixed-beam IMRT and helical tomotherapy treatments. VMAT treatment times varied from
2.1 to 4.6 minutes, IMRT treatment times varied from 7.9 to 11.1 minutes, and tomotherapy
treatment times varied from 4.0 to 7.0 minutes. Other work has shown similar decreases in
treatment time (Otto, Milette, and Wu 2007; Otto 2008; Verbakel et al. 2009). The possible
advantages of decreased treatment time include increased patient comfort and compliance,
increased patient throughput, and enhanced image guidance.
Another advantage of VMAT is increased monitor unit (MU) efficiency, meaning fewer
MUs are required to deliver the prescribed dose. Increased MU efficiency has two main
effects: reducing the wear and tear on the treatment machine, and decreasing leakage and
scatter dose. Rao et al. (2010) found that the VMAT treatments they planned used 18%
fewer monitor units than fixed-beam IMRT plans for the same geometries. Others have
found similar increased MU efficiency for VMAT treatments (Palma et al. 2008; Verbakel
et al. 2009).
Both decreased treatment time and increased MU efficiency have been achieved while
maintaining target coverage and OAR sparing similar to fixed-beam IMRT. In some cases,
VMAT has shown better OAR sparing than fixed-beam IMRT (Otto 2008; Palma et al. 2008;
Rao et al. 2010).
The main disadvantage of VMAT has been an increased optimization time as compared
to fixed-beam IMRT (Rao et al. 2010). However, optimization times have decreased, and as
techniques develop, this disadvantage will continue to be mitigated.
1.2 IMRT Patient Specific QA
Quality assurance (QA) in radiation therapy is the method used to ensure that the correct
amount of radiation is being delivered to the correct location. QA is performed routinely
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on all parts of the treatment process, from planning to delivery. The QA performed
on traditional treatments tends to consist of testing the capabilities of the system. For
example, the flatness and symmetry of the beam are measured to ensure they are within
predetermined tolerances. When a system is found to be within these tolerances, traditional
treatments are generally delivered without further testing of the individual plans, because
the possible errors are few and are quantifiable (Ramsey, Dube, and Hendee 2003).
IMRT treatments, on the other hand, are considerably more complex than traditional
treatments, and have a greater potential for delivery errors. In addition, IMRT often
delivers treatment fields of higher doses that come closer to critical structures. This makes
the consequences of misdelivery more pronounced than with traditional radiation therapy.
Because of this, IMRT treatments are verified individually prior to being delivered to the
patient. This is called “patient specific QA.”
IMRT patient specific QA has several purposes. First, IMRT consists of the addition
of many small fields delivered using precise positioning of the MLC, and the treatment
planning system may have difficulty accurately modeling this kind of complexity. Patient
specific QA ensures that the treatment planning system has accurately calculated the dose
for the planned treatment. Second, patient specific QA verifies that the large amount
of treatment data involved has been faithfully transferred from the treatment planning
system to the record and verify system. Third, patient specific QA ensures that the delivery
system is capable of delivering the fields as planned.
The most accurate QA possible would be performed by taking dosimetric measurements
inside of the patient during the treatment delivery. However, this is not a practical method.
Instead, treatment plans are typically copied onto a phantom geometry in which dosimetric
measurements can be taken. The treatment is delivered to the phantom and measured doses
are compared to calculated doses from the treatment planning system. The assumption is
made that if the planning system can accurately predict the dose to a phantom, it can also
accurately predict the dose to a patient.
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Figure 1.4: The composite delivery method for patient specific IMRT QA. The entire
treatment is delivered to the film or diode array in exactly the same manner as it is delivered
to the patient.
The QA of fixed-beam IMRT treatments generally consists of two major parts: an
absolute dose measurement to a reference point, and at least one measured plane of dose
distribution (Le´tourneau et al. 2004). There are two widely used methods of performing
the second of these parts:
(1) The first method is to deliver the entire treatment plan to the phantom while the
composite dose distribution is measured (see Fig. 1.4). Film (radiographic or radiochromic)
has been the typical dosimeter of choice for this method (Zeidan et al. 2006; Zhu et al. 2002),
although recently diode arrays have been developed that can also perform adequately
(Bedford et al. 2009; Jursinic, Sharma, and Reuter 2010). The advantage of this method
is that the actual treatment is being delivered to the phantom exactly as it is delivered
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Figure 1.5: The field-by-field delivery method for patient specific IMRT QA. Each beam
is delivered one at a time to film or a 2D diode array. The gantry remains in the same
position for each beam, and each beam is analyzed separately.
to the patient. Effects such as gantry sag and couch attenuation are incorporated into
the QA delivery. A historical disadvantage of this method has been a greater time and
resource commitment, as the technique has been performed using film. However, with
the increased use of diode based systems, this could become less of an issue. Another
potential drawback is that it may be more difficult to pinpoint the sources of error when
disagreement is found.
(2) The second method of verifying dose distributions is to deliver the IMRT beams
one at a time in a field-by-field manner to the phantom from a single gantry angle (see
Fig. 1.5); each beam is measured and compared separately (Van Esch et al. 2002). This can
be done using film, but it has become increasingly common to perform the measurements
using a 2D diode or ion chamber array (Buonamici et al. 2007; Le´tourneau et al. 2004). This
method has the advantage of being more comprehensive than the composite dose method,
meaning that errors may be more readily traced to their cause. Historically, it has also been
easier and quicker to perform this kind of QA when using an array setup. A disadvantage
of this method is that the gantry is not rotated during the treatment delivery; every field
is delivered from a single gantry angle. This removes effects that will be present during
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treatment such as gantry sag and couch attenuation. Also, the argument can be made that
the composite dose distribution is what actually matters, and errors in a single field are
less important as long as the full dose distribution is accurate. Finally, it has recently been
shown that the field-by-field method can mask important dosimetric errors (Kruse 2010),
and that it may not be predictive of clinically relevant dosimetric errors (Nelms, Zhen, and
Tome 2011).
1.2.1 IMRT Point Dose Analysis
For absolute point dosimetry, the QA comparison is relatively simple. The percent
difference between calculated and measured doses is determined, and the QA passes if the
difference is within some predetermined threshold (3%, for example).
1.2.2 IMRT Planar Analysis
The QA performed on planar measurements is more complicated than for a single point
dose. One method that can be used is to overlay a measured isodose distribution on top of
a calculated distribution and visually inspect the agreement. This method gives qualitative
information on the agreement between the calculated and measured distributions.
A more quantitative method of planar analysis is to simply consider the planar dose
as a collection of point doses and find the percent difference between the calculated and
measured distribution at every point. The percentage of points passing a predetermined
criterion (3%, for example) is reported. This method has the advantage of being straightfor-
ward and easy to perform. However, it is generally reliable only in regions where the dose
gradient is low. Figure 1.6 shows a profile of such an analysis between artificial measured
and calculated distributions. The measured distribution is shifted 1.5 mm to the left and
the dose is reduced by 1.5%. A very small spatial error leads to a disproportionately large
percent difference in high gradient regions.
In high gradient regions, the percent difference metric can be discarded in favor of
the distance to agreement (DTA) metric (see Fig. 1.7). For every dose point in some
distribution A, the surrounding area in distribution B is searched for a point of matching
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Figure 1.6: Sample percent dose difference profile comparison. The measured and
calculated doses are shown, along with the percent dose difference. The measured profile
is shifted 1.5 mm to the left and the dose is reduced by 1.5%. A ±3% dose difference
pass/fail criteria is also shown as the blue dotted lines. A small spatial error leads to a large
percent dose difference in high gradient regions.
DTA
A B
Figure 1.7: The distance to agreement method. For each point in some distribution A, the
surrounding region in distribution B is searched for points of matching dose. The distance
to the closest such point is the distance to agreement.
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Figure 1.8: Sample DTA profile comparison. The measured and calculated doses are
shown, along with the DTA. Here, the entire profile was searched for a matching dose, but
in typical practice, only a small area around each point is searched. The measured profile
is shifted 1.5 mm to the left and the dose is reduced by 1.5%. A 3 mm pass/fail criteria is
also shown as the blue dotted line. A small dose difference can lead to a large DTA in low
gradient regions.
dose. The distance from the point of interest to the closest point of matching dose is
called the DTA. Like the percent difference metric, the percentage of points passing a
predetermined criterion (3 mm, for example) can be reported. This metric is well suited for
regions of high gradient, but poorly suited for regions of low gradient (see Fig. 1.8). A
composite of the DTA and percent difference metrics can be used to give a more robust
method of analysis of planar dose distributions.
One method of combining the two metrics was discussed by Harms et al. (1998). In this
method, both the DTA and percent difference analyses are performed on a distribution.
Any point that passes either metric is considered a passing point, and the percent of points
passing is reported. Figure 1.9 illustrates how this composite method produces a binary
pass/fail result for any given point.
Low et al. (1998) suggested that such a metric is limited by its pass/fail nature. A
binary distribution does not lend itself well to display; therefore, the quantity displayed
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Figure 1.9: Sample binary DTA and dose difference composite comparison. The measured
profile has been shifted 2.5 mm to the left and the dose has been reduced by 2.5%. Passing
criteria are 3%/3 mm. Points where either the dose difference or DTA pass their respective
criteria are considered to pass the composite test.
is typically the dose difference. This yields a display that may show large disagreement
in high gradient regions. Also, a numerical metric may have more utility. For example,
consider the case shown in Fig. 1.10 of two different distribution pairs, each having 100%
of points passing the binary test described above. In the example shown, the criteria for
passing are 3% and 3 mm. In one case, all the points match up exactly. In the other, the
measured profile is shifted by 2.5 mm in one direction. The binary pass/fail test does not
detect this shift that, while still within the tolerance of the test, appears to indicate that
something is amiss in the second comparison.
Gamma Analysis
To overcome the potential problems with the binary test, a numerical method called
“gamma analysis” was put forth by Low et al. (1998) (see also Low and Dempsey (2003)).
Consider two dose distributions, a reference distribution and an evaluated distribution.
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Figure 1.10: Two sets of profiles with 100% of points passing the binary composite test.
The criteria used for the test are 3%/3 mm. In (a), the two profiles line up exactly, while in
(b), the measured profile is shifted 2.5 mm to the left.
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Gamma at every point in the reference is given by the equation
γ(rr) = min{Γ(rr, re)}∀{re} (1.1)
where
Γ(rr, re) =
√
r2(rr, re)
∆d2M
+
δ2(rr, re)
∆D2M
. (1.2)
Here, the terms rr and re are the reference and evaluated points, respectively. The terms
∆d2M and ∆D
2
M are the DTA and dose difference criteria, respectively. The terms
r(rr, re) = |re − rr| (1.3)
and
δ(rr, re) = De(re) −Dr(rr) (1.4)
are, respectively, the distance and dose difference between the reference and evaluated
points. The symbols Dr(rr) and De(re) denote, respectively, the reference and evaluated
doses at the points rr and re. Considering a single point in the reference distribution, Γ is
found for each point in the evaluated distribution (although in practice only a small region
around each point needs to be calculated). The smallest of these values becomes the γ at
that reference point. This is done for each reference point.
Like the binary pass/fail method, the gamma method uses a set of criteria for testing
(3%/3 mm, for example). A point is said to pass gamma if the gamma value at the point
is less than one. Figure 1.11 is a profile showing the results of a gamma test on the same
profiles as shown in Fig. 1.9. Also shown are the percent difference and DTA analyses.
Note that the area where both the DTA and percent difference tests fail corresponds to the
area where gamma is greater than one. Gamma analysis has been shown to be a suitable
quantitative method of determining the level of agreement between two dose distributions
(Low and Dempsey 2003; Stock, Kroupa, and Georg 2005).
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Figure 1.11: Sample gamma analysis. The profiles are shown in (a), along with the dose
difference and DTA analyses for reference. Plot (b) shows the profiles again, along with
gamma for each point. The criteria used for the gamma test were 3%/3 mm.
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1.2.3 AAPM Task Group 119
An important issue in any QA process is to determine a tolerance or action level. When
a QA result falls outside of this tolerance, some appropriate action is taken. During the
gradual development of IMRT patient specific QA, institutions generally determined their
own action levels based on their results. However, institutions had limited access to patient
specific QA results from other institutions to serve as a reference. To address this issue, the
American Association of Physicists in Medicine (AAPM) commissioned a task group (TG)
to gather data on QA results from several institutions performing IMRT QA. The results
were published as a report from AAPM TG 119 (Ezzell et al. 2009).
Each institution involved in TG 119 was given a common set of geometries for which
IMRT treatments were planned and on which QA was performed. (See Sec. 2.1 for more
information on the geometries.) For each treatment plan, point dose and planar film
measurements were taken for the full treatment plan. Also, field-by-field measurements
were taken, with most institutions using a 2D diode array. Point doses were analyzed
using the following formula:
%di f f =
Dmeasured −Dcalc
Dprescrip
× 100%. (1.5)
Dmeasured, Dcalc, and Dprescrip are the measured, calculated, and prescribed doses, respectively.
Gamma was calculated for the planar measurements using criteria of 3%/3 mm. The means
and standard deviations of the results from TG 119 are shown in Table 1.1.
These structures give a sampling of typical IMRT treatments. As such, the results
from planning and performing QA on these structure sets can be generalized to draw
conclusions about a large number of individual treatment plans. Institutions can also use
these common geometries to perform their own tests and compare the results to those
obtained in the TG report. For this reason, the structure sets from TG 119 were chosen for
use in the present work.
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Table 1.1: TG 119 results. Shown are the means and standard deviations of the four
different types of QA tests performed by the institutions involved in TG 119.
Test Metric Mean Standard deviation
High dose point Percent difference −0.2% 2.2%
Low dose point Percent difference 0.3% 2.2%
Composite film Percent passing gamma 96.3% 4.4%
(3%/3 mm criteria)
Field-by-field Percent passing gamma 97.9% 2.5%
(3%/3 mm criteria)
1.3 Motivation for Research
Because VMAT is a form of IMRT, clinics that have been using VMAT have been per-
forming patient specific QA on VMAT plans prior to delivery (Rao et al. 2010; Schreibmann
et al. 2009). Due to the rotational nature of VMAT treatment, it is not practical to perform
field-by-field QA on VMAT treatments. Therefore, the composite delivery method is
typically employed, using either film and ion chamber or 2D or 3D array of diodes (Bedford
et al. 2009; Jursinic, Sharma, and Reuter 2010; Korreman, Medin, and Kjaer-Kristoffersen
2009; Masi et al. 2011).
Those performing VMAT QA are typically using QA methods and action levels taken
from fixed-beam IMRT QA methods. Despite this, there has not yet been a study comparing
the results of such QA. As such, it is not yet clear that it is appropriate to apply fixed-beam
IMRT QA methods and action levels to VMAT QA. This study aimed to perform such a
comparison by systematically planning and performing QA on treatments using both the
fixed-beam IMRT and VMAT modalities, then analyzing the results.
1.4 Hypothesis and Specific Aims
Our hypothesis was that the results of VMAT and fixed-beam IMRT QA are not
significantly different. This hypothesis was tested using the following specific aims:
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1.4.1 Specific Aim 1: Develop IMRT and VMAT Plans for TG 119 Structures That
Meet Specified Dose Objectives
The TG 119 report provided four structure set geometries: a multitarget geometry,
a mock prostate geometry, a mock head and neck geometry, and a C-shape geometry.
Using a commercial treatment planning system, VMAT and fixed-beam IMRT plans were
constructed that either (a) met dose objectives specified in TG 119 or (b) fell within one
standard deviation of the results reported by institutions participating in TG 119.
1.4.2 Specific Aim 2: Deliver Planned Treatments to a Cylindrical Phantom and to a
2D Diode Array
For each test structure, VMAT and fixed-beam IMRT treatment plans were delivered
to a cylindrical water-equivalent phantom. Absolute dose measurements were made at
low and high dose points using a calibrated ion chamber. Planar dose measurements were
made in the phantom in the sagittal and coronal planes using film. The plans were also
delivered to a 2D diode array.
1.4.3 Specific Aim 3: Analyze the Collected Data and Test for Significance
The collected data was analyzed using the same methods as in TG 119. The film
and diode array measurements were compared to calculated planar doses using gamma
analysis with criteria of 3%/3 mm. Point dose data was analyzed using the percent
difference between the measured and predicted value. For each QA method and modality,
the results were averaged and tested for significance.
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Chapter 2
Methods and Materials
2.1 Experimental Geometry
The institutions participating in AAPM TG 119 were provided a set of four geometrically
distinct structure sets (see Fig. 2.1); these structure sets were used for this work. These
structure sets contained both avoidance and target structures. Each institution constructed
IMRT treatment plans for each of these structure sets in accordance with pre-specified dose
objectives. The structure sets are described below.
Figure 2.1: The four structure sets given to the AAPM 119 institutions included (a) a
multitarget geometry, (b) a mock prostate geometry, (c) a mock head and neck geometry,
and (d) a C-shape geometry.
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Figure 2.1(a) shows the multitarget geometry, which consists of three abutting cylindrical
targets, each with a length of 4 cm and a diameter of 4 cm. Each of these targets has a
different dose objective. Figure 2.1(b) shows the mock prostate geometry. The prostate is
approximately ellipsoidal and is 4.0 × 2.6 × 6.5 cm3 in the right-left (RL), anterior-posterior
(AP), and superior-inferior (SI) dimensions, respectively. The PTV is defined as a uniform
expansion of 0.6 cm around the prostate. The rectum is a cylinder of diameter 1.5 cm, and
the bladder is 5.0×4.0×5.0 cm3 in the RL, AP, and SI dimensions, respectively. Figure 2.1(c)
shows the mock head and neck geometry, which consists of a large central PTV with
parotid glands on either side and a spinal cord. The gap between the PTV and the spinal
cord is 1.5 cm. Finally, Fig. 2.1(d) shows the C-shape geometry, which consists of only two
structures, an outer target with an outer radius of 3.7 cm, and a central OAR with a 1 cm
radius. The gap between the two structures is 0.5 cm.
A set of dose objectives or goals for each geometry was provided to the institutions
participating in TG 119 (see Table 2.1). With one exception, the dose objectives consist of
a minimum or maximum dose to be received by a specified fraction of a structure. For
example, one of the dose objectives for the prostate PTV was D95 > 7560 cGy. This means
that 95% of the prostate PTV should receive at least 7560 cGy. (The lone exception is the
maximum dose objective given for the spinal cord in the head and neck structure set.) In
addition to the dose objectives shown, a more difficult version of the C-shape plan was
also constructed by the TG 119 institutions that had a lower dose goal for the central core.
This version was not used in this work.
Many of these objectives were achievable by some or all of the institutions. However,
some dose goals were difficult to meet, most notably the high dose PTV in the multitarget
geometry. For that geometry, the mean values of both dose parameters failed to meet the
specified dose objectives.
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Table 2.1: Dose goals for the TG 119 structures. The means and standard deviations of the
planning results of the institutions involved in TG 119 are also reported.
Planning Plan goal Mean Standard deviation Coefficient
parameter (cGy) (cGy) (cGy) of variation
Multitarget
Central target D99 >5000 4955 162 0.033
Central target D10 <5300 5455 173 0.032
Superior target D99 >2500 2516 85 0.034
Superior target D10 <3500 3412 304 0.089
Inferior target D99 >1250 1407 185 0.132
Inferior target D10 <2500 2418 272 0.112
Prostate
Prostate D95 >7560 7566 21 0.003
Prostate D5 <8300 8143 156 0.019
Rectum D30 <7000 6536 297 0.045
Rectum D10 <7500 7303 150 0.020
Bladder D30 <7000 4394 878 0.200
Bladder D10 <7500 6269 815 0.130
Head and neck
PTV D90 5000 5028 58 0.013
PTV D99 >4650 4704 52 0.011
PTV D20 <5500 5299 93 0.018
Cord maximum <4000 3741 250 0.067
Parotid D50 <2000 1798 184 0.102
C-shape
PTV D95 5000 5010 17 0.003
PTV D10 <5500 5440 52 0.010
Core D10 <2500 2200 314 0.141
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2.2 Treatment Planning
2.2.1 Objectives
The first specific aim of this work was to develop IMRT and VMAT plans for the TG 119
structure sets. The dose objectives provided in TG 119 were used as guidelines in the
treatment planning process in order to create plans that had complexity and modulation
similar to the TG 119 institutions’ plans. As previously stated, however, some of the dose
goals were difficult for various institutions to meet. It was thus deemed sufficient to either
meet the dose objectives specified in TG 119 or to fall within one standard deviation of the
mean results achieved by the TG 119 institutions. This ensured that the plans created in
this work achieved modulation similar to the plans constructed by the TG 119 institutions.
2.2.2 Planning Overview
The four structure sets and an accompanying CT image set were downloaded as DICOM
files from the AAPM website. These were imported into the Pinnacle3 treatment planning
system (Philips, Fitchburg, WI). A new patient was created in a research institution, and
the CT image set was added to the patient. A plan was created with the TG 119 CT set as
the primary image set using version 9.0 of the Pinnacle3 software. This plan was opened,
and the four structure sets were imported using the Import DICOM option. The plan was
exited and copied four times onto the CT image set of a cylindrical solid water phantom
using the QA Tools option. Each of these plans was named for one of the structure sets.
Each was then opened and all of the structures not corresponding to the plan’s structure
set were deleted, leaving only the structure set for which the particular plan was named.
The cylindrical phantom was used for the planar and point dose measurement portions
of this work (see Sec. 2.3.1 for more information on the cylindrical phantom). The cylindrical
phantom CT set contains a phantom boundary contour, inside of which the density is
overridden to 1.014 g/cm3, as this was the average density measured in the phantom.
A slice of the CT image is shown in Fig. 2.2. The head and neck structure set has been
imported and can be seen in the image.
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Figure 2.2: CT image of a slice of the cylindrical phantom. The head and neck structure set
has been imported onto the CT data set. Shown are the red PTV, the right and left parotids
in light blue and orange, and the cord in pink.
The treatments were planned directly on this phantom scan. All treatment planning was
performed using version 9.0 of the Pinnacle3 software. Both a fixed-beam IMRT treatment
and a VMAT treatment were planned for each of the four geometries. The general method
of planning is described below.
2.2.3 Initial Setup
When each plan was first opened, the CT couch was removed from calculation using
Pinnacle3’s Remove Couch tool. A dose grid was drawn to encompass the entire phantom.
A calculation point was placed inside the primary target to be used for plan renormalization.
Finally, a prescription was created for the calculation point, and the per-fraction dose and
the number of fractions were set to meet the prescription implied by the TG 119 dose
objectives.
Beams from the Elekta Infinity were placed onto the phantom using the machine BR1
Elekta (commission date: 23 April 2010 at 10:02 AM), with their isocenters located at the
center of the phantom. For both IMRT and VMAT treatments, 6 MV beams were used.
Table 2.2 lists the beam arrangements for each of the four geometries. For the IMRT plans,
step-and-shoot beams were added, using the number of beams specified in TG 119. An
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Table 2.2: Beam setup overview for each plan. The number and arrangement of the
IMRT beams followed the direction in TG 119, while for VMAT the number of arcs was
determined by how easy or difficult it was to meet the dose goals with one arc.
Number of Beam arrangement Collimator angle
beams/arcs
IMRT
Multitarget 7 50◦ from anterior 90◦
Prostate 7 50◦ from anterior 0◦
Head and neck 9 40◦ from anterior 0◦
C-Shape 9 40◦ from anterior 0◦
VMAT
Multitarget 1 CCW 175◦ → 185◦ 45◦
Prostate 1 CCW 175◦ → 185◦ 45◦
Head and neck 2 CCW 175◦ → 185◦, CW 185◦ → 175◦ 15◦
C-Shape 2 CCW 175◦ → 185◦, CW 185◦ → 175◦ 0◦
anterior beam was always present, and the remaining beams were distributed relatively
evenly around the arc. The collimator was originally set to 0◦ for all of the IMRT plans, but
was rotated as needed to better achieve the dose objectives. For VMAT plans, dynamic arc
beams were used. One beam with the gantry traveling counterclockwise from 175◦ to 185◦
was used initially; if this was found to be insufficient for meeting the plan goals, a second
beam traveling clockwise from 185◦ to 175◦ was added. A 45◦ collimator angle is often used
for VMAT (Otto 2009; Verbakel et al. 2009); the collimator was thus originally set at 45◦. As
with the IMRT plans, the collimator was rotated as needed to better achieve the dose goals.
2.2.4 General Optimization
IMRT plans were optimized using direct machine parameter optimization (DMPO).
The settings used for the IMRT plans are summarized in Table 2.3. These parameters
were chosen based on clinical practice at Mary Bird Perkins Cancer Center (MBPCC). The
maximum number of iterations was set, but optimization was stopped periodically to
make changes. Thus more or less iterations were executed as needed.
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Table 2.3: Optimization settings for IMRT plans. Plans were optimized using DMPO.
Exceptions to these settings are listed as footnotes.
Setting Value
Max iterations 45a
Convolution dose iteration 15b
Stopping tolerance 1e−05c
Apply tumor overlap function Unchecked
Allow jaw motion Checked
Split if necessary Unchecked
Max number of segments 90d
Min segment area 2 cm2 e
Min segment MUs 2
Compute final dose Checked
Use SVD for dose calculation No
Min number of leaf pairs 2
Min leaf end separation 0.2 cmf
Min overlap distance 2 cm
Max overlap distance 4 cm
a Multitarget=50
b Multitarget=20
c Multitarget=1e−06
d Multitarget=50, Prostate=70
e Multitarget=4 cm2
f Multitarget=1.5 cm
VMAT plans were optimized using the SmartArc option in Pinnacle3, which also
uses DMPO mechanics. The parameters used are summarized in Table 2.4. Again, the
parameters were chosen based on clinical practice. VMAT plans sometimes take a large
number of iterations to converge, so the optimization process was repeated as necessary,
without resetting the beams. Thus the number of iterations was generally more than the
maximum number given here.
The main objective in each plan was to get a uniform dose to the target volume. In
general, this was achieved by using Pinnacle3’s region of interest (ROI) type “Uniform
Dose” for the target volume objective. The target dose was set to the prescription dose
for the structure. A weight of around 20 was given to the target ROI. In some cases,
minimum or maximum dose or dose volume histogram (DVH) objectives were added if
26
Table 2.4: Optimization settings for VMAT plans. Plans were optimized using SmartArc.
Exceptions to these settings are listed as footnotes. For plans with two arcs, the second arc
traveled clockwise from 185◦ to 175◦.
Setting Value
Max iterations 70
Convolution dose iteration 20
Stopping tolerance 1e−05a
Apply tumor overlap function Unchecked
Allow jaw motion Checked
Final gantry spacing 4◦
Max delivery time 90 secb
Rotation direction CCW
Start angle 175
Stop angle 185
Constrain leaf motion 0.4 cm/deg
Compute intermediate dose Unchecked
Compute final dose Checked
Fine resolution ODM No
a Prostate=1e−06
b C-shape=100 sec
it was deemed necessary to push the system harder than simply using the uniform dose
option alone.
Avoidance structures were typically optimized using the “Max DVH” type of ROI.
This allowed shaping of the DVH to achieve the dose goals. Maximum DVH doses were
generally set below the actual dose objectives to allow for renormalization of the plan.
Weights were generally set to one, and increased as needed during the optimization process.
In some cases a “normal tissue” ROI was added with a max dose of around half of the
prescription dose, but in general little effort was put into reducing hot spots outside of the
treatment area.
After the initial objectives were set, the optimization process was started. The plan was
evaluated mainly using the dynamic DVH in Pinnacle3 during optimization. Depending
on how close the DVH appeared to achieve the dose goals, the optimization was either
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Table 2.5: Optimization parameters for the multitarget plans
ROI Objective type Target cGy % Volume Weight
IMRT
Central target Uniform dose 5000 20
Central target Max DVH 5200 10 5
Superior target Min DVH 2600 99 1
Superior target Max DVH 3100 10 5
Inferior target Min DVH 1350 99 1
Inferior target Max DVH 2100 10 5
VMAT
Central target Uniform dose 5000 10
Superior subvolume Uniform dose 2500 1
Inferior subvolume Uniform dose 1250 10
Central target Min dose 5000 25
Superior target Min dose 2500 25
Inferior target Min dose 1250 50
allowed to finish or was paused for adjustments to the dose objectives. Specific techniques
for achieving the dose goals for each structure set follow.
2.2.5 Plan Specific Optimization
Multitarget
The optimization objectives for the multitarget plans are shown in Table 2.5. For the
IMRT plan, a uniform dose objective was created for the central target as well as a max
DVH objective. The two abutting targets were given min DVH and max DVH objectives.
For the VMAT plan, the central target was given a uniform dose objective. However,
the system struggled to meet the objectives on the other two targets using the same method
as the IMRT plan. The technique employed here is one way to deal with secondary targets
that abut the primary target. A subvolume was created for each of the secondary targets
using the “ROI Expansion/Contraction” tool. This subvolume was separated from the
primary target by 7 mm. It was then given a uniform dose objective in the optimization
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Table 2.6: Optimization parameters for the prostate IMRT plan. The VMAT parameters
were identical except that the smaller volume rectum weight was set to 40.
ROI Objective type Target cGy % Volume Weight
Prostate PTV Uniform dose 7560 20
PTV ring Max dose 7400 1
Rectum Max DVH 6600 30 10
Rectum Max DVH 7100 10 20
Urinary bladder Max DVH 5000 30 1
Urinary bladder Max DVH 6800 10 1
Unspecified tissue Max dose 3750 1
window. All of the targets were given minimum dose objectives to help reduce the presence
of soft shoulders in the DVH.
Prostate
The optimization parameters for the IMRT prostate plan are shown in Table 2.6. The
VMAT parameters were identical to the IMRT parameters, except that the weight of the
smaller volume rectum objective was changed to 40. The PTV ring structure was a 9 mm
thick ring surrounding the PTV. Applying a “max dose” objective to this ring helped
prevent hot spots in the rectum, and allowed the rectal goal to be achieved. An unspecified
tissue structure was used to reduce hot spots outside of the treatment area.
Head and Neck
The parameters for the head and neck plans are shown in Table 2.7. The IMRT plan
goals were met with relatively little difficulty in optimization and the parameters were
fairly basic.
The VMAT plan required modifications of the initial objectives. A 1 cm ring was
expanded around the PTV and was given a max dose objective. Subvolumes were created
for the parotid glands, and rings were created around these subvolumes. These rings cut
into the PTV, and a PTV subvolume called 50only2 was created that did not include the
parotid rings. Finally an expanded cord contour was used to help lower dose to the cord.
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Table 2.7: Optimization parameters for the head and neck plans
ROI Objective type Target cGy % Volume Weight
IMRT
PTV Uniform dose 5000 10
PTV Min dose 5000 50
Cord Max dose 3500 50
Left parotid Max DVH 1500 50 25
Right parotid Max DVH 1500 50 25
VMAT
50only2 Max DVH 5400 5 50
50only2 Min DVH 5000 100 100
PTV Min dose 5000 25
PTV ring Max dose 5000 1
Cord Max dose 3700 25
Cord + 5 mm Max dose 3900 1
Left parotid sub Max DVH 1500 50 25
Right parotid sub Max DVH 1500 50 25
Parotid sub ring Max dose 5100 1
Unspecified tissue Max dose 3500 0.5
C-shape
The parameters for the C-shape plans are shown in Table 2.8. The IMRT plan employed
an 8 mm PTV ring to provide an area for the dose to decrease between the PTV and the
core. An unspecified tissue contour helped avoid hot spots outside of the treatment area.
The VMAT plan included a minimum dose objective for the target to help reduce the soft
shoulder. A 7 mm ring around the core was added to push the system further in reducing
the core dose.
2.2.6 Evaluation of the Plan
When optimization was complete, the final dose was computed using the adaptive
convolution algorithm. However, immediately following optimization, the plans generally
required renormalization to meet the dose goals. A tabular DVH was used to quantitatively
evaluate the dose parameters during normalization. An example of a tabular DVH is
shown in Fig. 2.3. For every ROI, the volume receiving a given dose can be read off. This
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Figure 2.3: Tabular DVH example. The row and column headings are in cGy, and the cells
are in cm3.
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Table 2.8: Optimization parameters for the C-shape plans
ROI Objective type Target cGy % Volume Weight
IMRT
PTV Uniform dose 5000 20
PTV ring Max dose 4800 1
Core Max DVH 2100 10 50
Unspecified tissue Max dose 2500 0.5
VMAT
PTV Uniform dose 5000 20
PTV Min dose 5000 20
Core Max DVH 2000 10 20
information was used to determine the values of the parameters of interest. By adjusting
the plan normalization in the prescription dose window (shown in Fig. 2.4), the plan
was normalized until the primary target volume just achieved the dose goal. At that
point, if any organs at risk did not achieve their dose goals, the plan was returned to the
optimization process for further work.
2.2.7 Data Export
Point and Planar
Once all of the dose goals were met for a given plan, it was ready to be delivered.
Both planar and point dose measurements were made, so planar dose and point dose
calculations were extracted from Pinnacle3.
For every plan, several calculated point doses were recorded. Table 2.9 lists the positions
for each point dose calculation. These were chosen based on the recommended point dose
measurements in TG 119. In general, a point dose was measured in each target and in at
least one OAR. Locations of calculated point doses corresponded to the location of the
center of the ion chamber inside the phantom (see Sec. 2.3.1 for more information on the
phantom used).
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Figure 2.4: Prescription dose window. The normalization was adjusted to achieve the
desired dose goal in the primary target.
Table 2.9: Point dose calculation and measurement locations
Geometry Number of points Point descriptions
Multitarget 3 One point located within each of thethree targets
Prostate 3
One point located in the prostate PTV,
one in the bladder, and one in the
rectum
Head and neck 2 One point in the PTV, and one in thecord
C-Shape 2 One point in the PTV, and one in thecentral core
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Table 2.10: Settings used for exporting planar dose files
Setting Value
Medium Primary data
SPD 100 cm
Beams Sample trial
Resolution 0.1 cm
X Dimension 230
Y Dimension 230
Format ASCII
Before extracting the calculated doses, the prescription was reduced to a single fraction,
as only a single fraction was delivered for each measurement. For each plan, the calculated
doses were recorded from Pinnacle3’s “Point Of Interest dose” table.
Planar doses in Pinnacle3 were calculated using a separate beam. For each plan, two
static beams were added with the center of the phantom at isocenter. One beam was
placed at 0◦ for a coronal plane and one at 90◦ for a sagittal (note that the Elekta defines
0◦ as a top down beam). They were given 20 × 20 cm2 square fields, and zero monitor
units. The beams were calculated prior to calculating the planar dose. The planar dose
tool in Pinnacle3 was used to create planar dose files, and the settings used are shown in
Table 2.10. The planar dose files were exported from Pinnacle3, then retrieved via FTP.
MapCHECK and MapPHAN
In addition to using a phantom for measurements, a 2D diode array was used (see
Sec. 2.3.1). Planar dose files were also required for this device. To accomplish this, every
plan was copied to a CT scan of the MapCHECK with MapPHAN combination. The same
steps were followed to obtain a planar dose as described in the previous section, with a
few exceptions. First, the number of monitor units was set to be the same as what was
used for the original plan. This meant that the exact same treatment would be delivered
to MapCHECK as to the cylindrical phantom. Also, only a coronal planar dose file was
created for each geometry.
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Figure 2.5: Elekta Infinity linear accelerator
MOSAIQ
The plans were exported from Pinnacle3 and imported into MOSAIQ (Elekta AB,
Stockholm, Sweden) for treatment delivery. The plans were exported from Pinnacle3 using
the “Export DICOM” tool. A research patient named “Mancuso, Thesis” was created in
the MOSAIQ system with the same MR# as the patient in Pinnacle3 (MR#: A101477). Then
the treatments were imported into MOSAIQ using the “RTP Import” tool.
2.3 Experimental Measurements
For each planned geometry, several types of measurements were taken, using film, ion
chamber, and a 2D diode array. Coronal and sagittal film planes were measured three
times each, and each point dose was measured five times. Diode array measurements
were also taken five times in the coronal plane for each geometry. This section details the
materials and procedures used for each of the measurement methods.
2.3.1 Measurement Materials
The treatments were all delivered using an Elekta Infinity linear accelerator system
(Elekta AB, Stockholm, Sweden) (see Fig. 2.5) located at MBPCC in Baton Rouge, Louisiana.
The Infinity can deliver both fixed-beam IMRT and VMAT treatments. It includes on-board
kV cone beam CT imaging and MV planar imaging. The particular unit used can deliver
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Figure 2.6: Cylindrical “cheese” phantom
Figure 2.7: Cylindrical phantom separated into semicylinders
photon energies of 6, 10, and 15 MV, and electron energies of 7, 9, 10, 11, 13, 16, and 20
MeV. The nominal dose rates available are 500, 250, 125, 65, and 30 MU per minute.
The phantom used for planar film and point dose measurements was a cylindrical solid
water phantom, or “cheese” phantom (Tomotherapy, Inc., Madison, WI), shown in Fig. 2.6.
The cylinder has a radius of 15 cm and a height of 18 cm. The phantom splits in half to
allow film placement between the two semicylinders (see Fig. 2.7). It is held in place on a
36
Figure 2.8: Exradin A1SL ion chamber
small stand that allows the phantom to be rotated about its central axis, thus allowing both
sagittal and coronal film measurements. A linear series of holes extends along one face of
the phantom. These holes are designed to hold an A1SL ion chamber. The holes are 1 cm
apart, except for at the split where there is no hole. The hole directly below the split is
0.5 cm from the split, and the next hole is 1.5 cm below that (the intention being to allow
point measurements as close as possible to the film plane). When not filled with an ion
chamber, these holes are plugged with solid water.
Point dose measurements were acquired using a 0.057 cc Exradin A1SL ion cham-
ber (Standard Imaging, Inc., Middleton, WI), shown in Fig. 2.8 (serial number 330320).
The chamber was connected to a Keithley 614 electrometer (Keithley Instruments, Inc.,
Cleveland, OH) (see Fig. 2.9) for all data collection (serial number XW100989).
Planar dose measurements were made using film. Initially, radiographic EDR2 film was
used (Eastman Kodak, Rochester, NY), but after numerous tests, it was determined that
the available processor did not develop the film uniformly. Therefore, film measurements
were made using radiochromic film, which requires no processor as it is self-developing.
Gafchromic EBT2 film (International Specialty Products [ISP], Wayne, NJ, shown in Fig. 2.10)
was tested and determined to be sufficient for the film measurements in this work. EBT2
film consists of a radiosensitive active layer sandwiched between two layers of polyester.
37
Figure 2.9: Keithley 614 electrometer
Figure 2.10: EBT2 film
The active layer darkens when exposed to radiation, and can be used to read doses up to
40 Gy when it is read using the green channel, although the typical range of measurements
is 1 cGy–10 Gy. The yellow appearance of the film is due to a marker dye included in the
active layer. This marker dye distinguishes EBT2 film from EBT film, and has two benefits.
One, it allows measurements of the film response independent of thickness changes in the
active layer, and two, it absorbs lower wavelength visible light, making EBT2 significantly
less sensitive to ambient light than EBT film (Andre´s et al. 2010; International Specialty
Products 2009).
2D diode array measurements were taken using the MapCHECK with MapPHAN
combination (Sun Nuclear, Melbourne, FL) (see Fig. 2.11). The MapCHECK is a 2D diode
38
Figure 2.11: MapCHECK device and MapPHAN phantom. The MapCHECK slides into
the MapPHAN for rotational delivery measurements.
array with 445 diodes in a 22 × 22 cm2 plane. The active detector area is 0.8 × 0.8 mm2.The
minimum diode spacing in the central 10 × 10 cm2 region is 7.07 mm and in the outer
region is 14.14 mm. The MapPHAN is a water equivalent case designed to house the
MapCHECK for rotational delivery measurements. The MapCHECK device is connected
to a computer during delivery, and the MapCHECK software records the data collected.
2.3.2 Point and Planar Dose Calibration
For point dose measurements, the ion chamber was calibrated for each measurement
session. The calibration procedure recommended in TG 119 was used, and its description
follows. In Pinnacle3, a plan was made using 10× 10 cm2 parallel opposed AP:PA fields on
the cylindrical phantom. A dose of 200 cGy was prescribed to the chamber location closest
to the geometric center of the phantom. This plan was exported to MOSAIQ. With the
phantom aligned (alignment procedure described in Sec. 2.3.3) and the chamber inserted
into the phantom in the appropriate hole, the plan was delivered to the phantom, and
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Figure 2.12: Calibration film with eight 3 × 3 cm2 squares of varying doses
the electrometer reading was recorded. This gave a cGy/reading ratio, r. For subsequent
measurements, r was used to obtain measured dose, Dm, using the equation
Dm = Em × r . (2.1)
Here, Em is the electrometer reading corresponding to the measurement m. This method
was recommended in TG 119 to reduce the effect of daily linac output variations. For each
dose calibration measurement, the ion chamber dose was also calculated using the ND,w of
the chamber and the Pelec of the electrometer, with a temperature and pressure correction.
In all measurement sessions, the dose calculated using the temperature/pressure correction
was within 0.6% of the 200 cGy calculated dose to the chamber.
For each session of film data collection, a calibration film was irradiated following the
procedure described by Childress, Dong, and Rosen (2002). A blank film was irradiated
at isocenter in the portrait orientation with 5 cm backscatter and 10 cm buildup of solid
water. The delivered calibration fields resulted in a series of eight dose squares of regularly
spaced known doses, as shown in Fig. 2.12. The following doses (in cGy) were delivered
to their respective squares: 35.6, 66.6, 97.5, 129.3, 161.8, 191.3, 222.2, 256.1. In addition, a
point at the center of the calibration film had a measured dose of 5.4 cGy. These covered
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the full range of doses used in this study. The calibration film was used along with a blank
film to calibrate all the films from a session.
2.3.3 Point and Planar Dose Measurements
This section describes the methods of measuring the point and planar doses in the
cheese phantom. The basic method of setting up the cheese phantom was very similar for
both film and point dose measurements, and is described first. The collimator, gantry, and
couch rotation were all set to 0◦ prior to alignment, and the treatment field was opened
to make sure the light field crosshairs were visible. The phantom was placed on the
treatment couch and aligned to the treatment room lasers such that the geometric center of
the phantom coincided with the isocenter of the linear accelerator. The machined grid on
the phantom was aligned to the light field crosshairs of the linear accelerator. With the
phantom in the correct lateral and longitudinal position, the top semicylinder was carefully
removed to expose the flat surface of the phantom. The optical distance indicator (ODI)
was then used to bring the cylinder center to 100 cm SSD, thus bringing the phantom to
the correct vertical position. The top semicylinder was then placed back into position.
For each point dose measurement, the following procedure was followed. The ion
chamber was placed in the appropriate hole in the phantom for the current measurement.
All point dose measurement locations were located along the vertical line on which the
holes fell (except for two measurements in the multitarget structure set, which presented a
unique challenge that is discussed below). The phantom was checked to ensure it was
in the correct location, and the entire treatment was delivered. The electrometer reading
was recorded after each delivery. In between repeated measurements at the same point,
the treatment couch was perturbed and realigned to simulate inter-treatment positional
variations that occur in clinical practice.
The multitarget structure set consists of three abutting cylindrical targets. TG 119 called
for point dose measurements in each target. The targets are oriented in the superior-inferior
direction, which is perpendicular to the chamber position line in the phantom. The ion
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chamber could not be simply moved to a new hole for measurement; instead, the entire
phantom had to be translated to place the chamber in the correct location. To compensate
for the changed treatment setup, new plans were created in Pinnacle3 that simulated the
new setup. The beams were moved 4.3 cm either superior or inferior, depending on the
target being measured, and the new chamber dose was recorded. During measurement, the
couch was shifted the appropriate 4.3 cm after the initial alignment to place the chamber at
the correct location.
It was noted after taking all of the multitarget point dose data that the phantom had
been rotated 180◦ from its nominal orientation. As such, point dose measurement locations
were displaced by 0.5 cm. To compensate for the measurement shift, the point doses were
moved in Pinnacle3 and dose was recalculated.
For film measurements, the following procedure was followed. With the phantom
fully intact, the alignment with the light field was rechecked. The top semicylinder was
removed from the phantom and set aside. A piece of EBT2 film, labeled with the name of
the plan to be delivered, was placed on the phantom in landscape orientation. The film
was taped to the phantom and the superior-left corner (from the patient’s perspective) was
marked with an arrow. The collimator was opened to an 18 × 18 cm2 field. For registration
purposes, the edges of the field were marked on the film using a fine tipped permanent
marker, at the points where the crosshairs intersected the field edge (see Fig. 2.13). (The
“field edge” is typically defined at the point where the light field fades completely to dark.
However, on the Elekta Infinity used for this work, the lateral field edges are defined in
the middle of the fading region. The longitudinal field edges are defined as normal.) The
top semicylinder was carefully placed back into position, and the phantom was checked
to make sure that its location had not been disturbed. If the film was a sagittal film, the
phantom was then rotated 90◦ to place the film in the correct orientation.
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Figure 2.13: EBT2 film in place on the cylindrical phantom. An arrow marks the in-left
position, and registration dots mark the edges of an 18 × 18 field.
The treatment plan was then delivered to the film-phantom setup. The film was
removed and stored for later digitization, and the process was repeated for the next
measurement.
The cheese phantom allows ion chamber and film measurements to be taken at the
same time. The point dose measurements in the central PTVs of the multitarget, prostate,
and head and neck geometries were performed with EDR2 film in place, as these point
dose measurements were taken prior to the switch to EBT2 film. Three of the point dose
measurements in the core of the C-shape geometry were taken with EBT2 film in place.
The rest of the point dose measurements were taken without film in place.
2.3.4 MapCHECKMeasurements
The MapCHECK device requires two calibration types. One is the dose calibration,
which is performed before every MapCHECK session. The central diode is calibrated
to a known dose, which minimizes the effect of daily linac output variation. The other
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calibration is the array calibration, which determines the ratio of each diode’s reading to
the central diode reading. By combining this with the dose calibration, the dose at each
diode can be calculated. This work used the array calibration used for clinical work at
MBPCC.
The dose calibration was performed prior to measurements using the procedures of
MBPCC. The MapCHECK, without the MapPHAN, was placed on the treatment couch
and the light field crosshairs were aligned to the diode array. The electronics portion of the
device was placed inferior to the diode array, away from the gantry. 3 cm of solid water
was placed on top of the diode array portion of the device. The ODI was activated and the
top of the solid water was set to 95 cm SSD. The MapCHECK has 2 cm of water equivalent
buildup built in, so the radiological depth was 5 cm. The MapCHECK program was set to
collect a calibration dose, and a 10 × 10 cm2 field delivered 100 MU to the device. The dose
delivered during the calibration was 95.4 cGy, which was entered into the MapCHECK
program.
With the MapCHECK device and program calibrated, the system was ready to take
measurements. The MapCHECK device was placed inside the MapPHAN phantom and
placed on the treatment couch. The device was aligned in the following manner. The gantry
crosshairs were aligned to the crosshairs on the top of the MapPHAN. To put the detector
plane at isocenter, the ODI on the top of the MapPHAN was set to 95.7 cm, since the
distance from the top surface to the detector plane is 4.3 cm. Only coronal measurements
were acquired with the MapCHECK device.
For each diode array measurement, data collection was started in the MapCHECK
software. The treatment was delivered, and the data collection was stopped. The measured
dose was saved, and the process was repeated for the next plan. Array and dose calibrations
were saved in the collected data file. Similar to the point dose data collection, the couch
was perturbed in between consecutive deliveries of each plan.
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2.4 Data Analysis
2.4.1 Point Dose Analysis
The measured point doses were compared to the point doses calculated in the treatment
planning system. A simple percent difference calculation was used. Based on the
recommendation in TG 119, this was calculated using the formula
%di f f =
Dmeasured −Dcalc
Dprescrip
× 100%. (2.2)
Dmeasured, Dcalc, and Dprescrip are the measured, calculated, and prescribed doses, respectively.
TG 119 recommends using the prescribed dose rather than the local predicted dose in the
denominator to avoid overstating the differences in low dose areas.
2.4.2 Film Scanning
The EBT2 films were digitized using a 16-bit Vidar DosimetryPro Advantage scanner
(Vidar Systems Corporation, Herndon, VA) (see Fig. 2.14). Film is transported past a
line of detectors which capture the image. MBPCC owns both a white light scanner
and a red scanner. An initial investigation of the red scanner revealed that it exhibited
excessive nonuniformity (approximately a 10% variation in recorded light response) across
a uniformly blank film, as shown in Fig. 2.15. By contrast, Fig. 2.16 shows the same film
scanned on the white scanner, which showed an approximate 3% variation across the film.
Therefore, the white scanner was chosen for this work.
Radiochromic film has been shown to respond differently depending on whether the
film is scanned in the portrait or landscape orientation (Zeidan et al. 2006). According to
ISP documents included with the film, EBT2 film also responds differently depending on
the particular face of the film that is facing the scanner. The reason for this is that EBT2
film is not symmetrical; the polyester outer layers are of differing thicknesses depending
on the face, as seen in the film cross section shown in Fig. 2.17. Because of these issues,
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Figure 2.14: Vidar DosimetryPro Advantage scanner with white light source
care was taken to scan all films in a consistent manner. The procedure that was used is
described below.
Each film has a small slit in one corner that identifies the orientation of the film. Each
film was irradiated as described in Sec. 2.3.3, with the slit in the same corner as the arrow
marking the in-left position. This placed the thinner polyester laminate facing up. Each
film was scanned in landscape orientation, with the arrow in the upper left corner of
the film during scanning. This kept the scanning orientation consistent. This particular
orientation was chosen because the resulting scanned image was in the correct orientation
with respect to the calculated planar dose from the treatment planning system, without
requiring any rotating or reflection of the image.
To further suppress scanner nonuniformity using the white light Vidar scanner, film
was placed in the center of the scanning area, rather than up against the built in film guide.
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Figure 2.15: Horizontal profile of EBT2 film scanned on the red Vidar scanner. The y-axis
is in pixel values (the cGy text notwithstanding), and the x-axis is in cm.
Figure 2.16: Horizontal profile of EBT2 film scanned on the white Vidar scanner. The y-axis
is in pixel values (the cGy text notwithstanding), and the x-axis is in cm.
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Topcoat - 5 microns
Active Layer - 30 microns
Polyester Substrate - 175 microns
Adhesive Layer - 25 microns
Polyester Overlaminate - 50 microns
Figure 2.17: Cross section of EBT2 film. Image from International Specialty Products (2010).
A replacement film guide was constructed using a ruler affixed to the scanner to ensure
that films were placed in the same location for each scan.
To further reduce the effect of scanner nonuniformity on the calibration films, they
were scanned four times, once for each of the four rows of two dose squares. For each scan,
the row being focused on was placed as close as possible to the center of the scanner, where
the majority of the film data of interest was also located. This allowed each calibration
row to be scanned by the same detectors and reduced the nonuniformity effect on the
calibration films.
The Vidar scanner was controlled using version 5.2 of the RIT113 film analysis software
(Radiological Imaging Technology, Inc., Colorado Springs, CO). Films were scanned at a
resolution of 0.178 mm per pixel, and a 5 × 5 pixel median filter was applied to the data.
The files were saved in a proprietary RIT format.
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2.4.3 Film Analysis
Films were converted to dose, registered, and normalized using the RIT software.
Gamma calculations were performed using in-house software.
Each film was converted from pixel value to dose using the calibration film from its
measurement session. Using the scans of the calibration film and a blank film, a calibration
file was created using the RIT “Perpendicular Dose Calibration” tool. This file consisted of
10 points of scanner response versus dose—eight from the calibration film squares, one
from the center of the calibration, and one from the blank film. The calibration file used a
piecewise polynomial interpolation.
Each film was opened as the reference image in the RIT software. The appropriate
calibration file was applied and embedded into each film scan. Embedding simply added
the calibration information to an ASCII header file associated with each film scan file; it
did not change the original scanned data.
The film scan was moved to the target image spot in RIT, and the corresponding ASCII
planar dose file from Pinnacle3 was opened as the reference image. The registration tool
was selected, and a saved registration was applied. The saved registration placed four
registration points onto both the calculated and measured data fields. The points on the
calculated image were defined to be at the points corresponding with the crosshair edges
of an 18 × 18 cm2 field. The saved registration was defined in terms of pixels and allowed
subpixel registration. RIT has an option to apply a template to the reference or target
that is defined in terms of centimeters. However, this option has an error in coding that
incorrectly placed the points one half of a pixel away from their true locations in each
direction. This resulted in a 0.5 mm error in both the x and y directions, and was deemed
unacceptable.
With the registration points in their correct location on the calculated image, the
points on the film image were moved manually to the marked spots visible on the film
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Table 2.11: Crop dimensions used in RIT before IMRT analysis
Orientation X1 (cm) X2 (cm) Y1 (cm) Y2 (cm)
IMRT
Multitarget Coronal 4.5 18.5 2 20
Sagittal 4.5 18.5 2 20
Prostate Coronal 5.5 17.5 4 16
Sagittal 4.5 19 4 16
Head and neck Coronal 2.5 20.5 1.5 16
Sagittal 2.5 20.5 1.5 16
C-Shape Coronal 5 18.5 4 18
Sagittal 5 20 4 18
VMAT
Multitarget Coronal 4.5 18.5 1.5 21
Sagittal 4.5 18.5 1.5 21
Prostate Coronal 5.5 18 4 16
Sagittal 5.5 18 4 16
Head and neck Coronal 4 20 1.5 16
Sagittal 4 21 1.5 16
C-Shape Coronal 5 18.5 4 18
Sagittal 5 20 4 18
(corresponding to the 18 × 18 cm2 field edges). The registration was then applied and
saved.
When the images were registered, RIT automatically resampled the target image to the
same grid as the reference image. This is the reason that the film image was placed as the
target; if the high resolution film were the reference, the analysis calculation time became
prohibitively long. Each film was then cropped to a smaller area of interest. Table 2.11 lists
the crop dimensions for each treatment and orientation. The images were then normalized
to each other using the “Normalize to Area” option. A box covering a majority of the high
dose PTV was used for normalization.
With the images registered, normalized, and cropped, the image set was ready for
gamma analysis. The RIT software has the ability to perform gamma analysis, but using
this capability resulted in a high number of failing pixels in high dose gradient regions
(see Fig. 2.18(a)). The source of these artifacts is not immediately clear, as the algorithm
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(a) (b)
Figure 2.18: Comparison of RIT and in-house gamma analysis results of a coronal head
and neck delivery. (a) is from the RIT software, and (b) is the result from the in-house
gamma analysis performed in Matlab. Note that in the RIT image there are lines of failing
pixels in the high gradient regions. The in-house image does not show these lines of failing
pixels, but other areas fail in a fashion similar to the RIT analysis image. Gamma criteria of
3%/3 mm and a threshold value of 10% were used in both cases.
RIT uses to calculate gamma is not available. However, it was noted that if the resolution
of the calculated planar dose file was increased (consequently also increasing the film
resolution once it was resampled onto the calculated dose grid), the artifacts diminished.
It appears that the RIT software doesn’t adequately interpolate in its gamma calculation.
However, increasing the grid size was undesirable as it greatly increased the calculation
time. Therefore, an in-house program was developed using Matlab (MathWorks, Natick,
MA) to calculate gamma. This program employed the algorithm described by Ju et al. (2008).
Briefly, this algorithm used a geometric interpretation of the gamma metric, allowing
interpolation-free calculation. A result from this software is shown in Fig. 2.18(b). The
in-house method did not exhibit the high gradient artifacts seen in the RIT gamma analysis.
The in-house gamma analysis program was not able to read the proprietary film data
format used by RIT. Therefore, after registration and normalization in RIT, each film
and planar dose image were exported from RIT into a Matlab-specific format. These files
were read by the in-house software, which calculated gamma and displayed the result
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Figure 2.19: Batch analysis window in the MapCHECK software
(see Fig. 2.18(b)), which displayed the film image where gamma passed, and the gamma
value where gamma failed. The gamma criteria were set at 3% and 3 mm. The image was
thresholded at 10%, meaning that all pixels where the calculated dose was less than 10% of
the normalization dose were not included in the gamma calculation.
The in-house program also recorded the percent of pixels passing the gamma test for
each comparison in a comma separated value file.
2.4.4 MapCHECK Analysis
The MapCHECK data was analyzed using the MapCHECK software. A gamma analysis
using criteria of 3% and 3 mm was performed for each measurement. This was done
using the “File Manager” in the MapCHECK software, which has an option to perform
batch analysis on several measurements at once. The batch analysis window is shown in
Fig. 2.19. The analysis box in the upper right corner allows the user to specify the type of
analysis performed. There was no need to perform relative dose measurements so absolute
dose was used. Similar to the film analysis, points below the 10% threshold dose were
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excluded. The “Auto Calc Shift” option, which attempts to make small shifts in the data to
improve agreement, was unchecked for this analysis. In the MapCHECK preferences, the
following boxes were checked under “Analysis”: “Region Of Interest Analysis,” “Van Dyk
% Difference,” and “Apply Measurement Uncertainty (MapCHECK Only).”
For each measurement, a comparison report like the one seen in Fig. 2.20 was created.
This report contained all of the important data about the test performed, including test
parameters, the number and percentage of points passing, and the normalization values
(even if the data was not actually normalized). The top left image is the contour plot
produced from the measured data points, with the diode locations shown. The top right
image is the contour plot from the calculated data, again with the diode locations shown.
The bottom left image is a contour plot of the calculated data, with passing diodes not
shown and failing diodes shown in either red (for overdoses) or blue (for underdoses). The
green diode is the normalization diode, which is shown even when no normalization was
performed. The green line corresponds to the horizontal dose profile shown in the bottom
right image. In the profile, the calculated dose is shown as the black line, passing diodes
are yellow, and failing diodes are blue or red. The percent of diodes passing gamma was
recorded for each measurement.
The MapCHECK software also includes a correction called the arc calibration matrix.
This is meant to correct for an observed directional dependence in MapCHECK mea-
surements for some devices manufactured before 2005. No directional dependence was
observed in the MapCHECK device used in this work, so the correction was not used.
2.4.5 Statistical Tests
The Wilcoxon rank-sum test was used to determine if differences between modalities
were significantly different. The rank-sum test was chosen over a t-test because the
normality of the data distributions was in question (see Sec. 4.2.1), and the rank-sum test
does not assume a normal distribution of data. However, this also makes the Wilcoxon
rank-sum test less powerful than a t-test. Two different classes of comparisons were made.
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Figure 2.20: Sample comparison report from MapCHECK results
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(1) Site-specific comparisons were made between identical measurement setup. For
example, the five point dose measurements in the central target of the IMRT multitarget
treatment were compared against the five point dose measurements at the same location
in the VMAT multitarget treatment. This method of comparison was only used for the
point dose data and the MapCHECK data. It was not used for the film data because the
film data only took three measurements for each film setup, and the Wilcoxon rank-sum
test lacked the power to conclude a statistically significant difference (p < 0.05) for such a
small sample size.
(2) Global comparisons were performed between all of the IMRT and VMAT data of
each measurement type. In each global comparison, the mean values from each set of
site-specific measurements were used for the statistical tests, rather than all of the values
measured. This was because the individual measurements for each specific site were found
to have little variation when compared to the variation of measurements between sites. This
means that the individual measurements did not constitute independent measurements
for the purposes of a statistical test.
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Chapter 3
Results
3.1 Planning Results
Planned dose objectives and treatment planning results for each structure set geometry
are displayed in Table 3.1. Results that met the TG 119 dose goals are highlighted in green,
and values that did not meet the dose goals but fell within one standard deviation of the
mean values reported by the institutions participating in TG 119 are highlighted in yellow.
There were no instances in which plan results failed to meet at least one of these standards.
Figures 3.1–3.8 show isodose distributions and DVHs for each of the treatment plans.
For the multitarget structures set (Figs. 3.1 and 3.2), a coronal plane is shown; for the others,
axial planes are shown.
3.2 Point Dose Results
For each point dose measurement location, dose was measured for five treatment
deliveries in the cylindrical phantom. Table 3.2 lists the dose measurements taken for
each of the points, along with the dose calculated by Pinnacle3. Table 3.3 lists the percent
Figure 3.1: Multitarget IMRT isodose distribution and DVH
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Table 3.1: Treatment planning results. For each parameter, the TG 119 goals and results
are shown, along with the values obtained for the IMRT and VMAT plans created in the
current study. Results that met the TG 119 objectives are highlighted in green, while results
that did not meet the TG 119 objectives but still fell within one standard deviation of the
mean are shown in yellow.
Planning Plan goal Mean Standard deviation IMRT VMAT
parameter (cGy) (cGy) (cGy) (cGy) (cGy)
Multitarget
Central target D99 >5000 4955 162 4857 5132
Central target D10 <5300 5455 173 5475 5532
Superior target D99 >2500 2516 85 2543 2648
Superior target D10 <3500 3412 304 3266 3410
Inferior target D99 >1250 1407 185 1277 1255
Inferior target D10 <2500 2418 272 2541 2398
Prostate
Prostate D95 >7560 7566 21 7609 7560
Prostate D5 <8300 8143 156 7784 7813
Rectum D30 <7000 6536 297 6846 6830
Rectum D10 <7500 7303 150 7464 7473
Bladder D30 <7000 4394 878 4868 4627
Bladder D10 <7500 6269 815 6930 6941
Head and neck
PTV D90 5000 5028 58 5203 5147
PTV D99 >4650 4704 52 4763 4755
PTV D20 <5500 5299 93 5385 5439
Cord maximum <4000 3741 250 3940 3951
Left Parotid D50 <2000 1798 184 1875 1850
Right Parotid D50 <2000 1798 184 1833 1910
C-shape
PTV D95 5000 5010 17 5001 5007
PTV D10 <5500 5440 52 5330 5463
Core D10 <2500 2200 314 2489 2163
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Figure 3.2: Multitarget VMAT isodose distribution and DVH
Figure 3.3: Prostate IMRT isodose distribution and DVH
Figure 3.4: Prostate VMAT isodose distribution and DVH
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Figure 3.5: Head and neck IMRT isodose distribution and DVH
Figure 3.6: Head and neck VMAT isodose distribution and DVH
Figure 3.7: C-shape IMRT isodose distribution and DVH
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Figure 3.8: C-shape VMAT isodose distribution and DVH
Table 3.2: Point dose measurements: Dose. The measured doses are given for all five
measurements taken at each point discussed in Table 2.9. The dose calculated by Pinnacle3
is included for each point.
Plan Point Calculated Dose measurements
description dose (cGy) (cGy)
IMRT
Multitarget 50 Gy target 214.7 213.7 213.7 214.2 214.2 213.7
25 Gy target 121.7 119.6 119.1 118.1 117.6 118.1
12.5 Gy target 64.2 60.1 60.1 60.1 59.6 59.0
Prostate PTV 184.0 182.5 182.5 182.5 183.1 182.5
Rectum 132.9 134.4 133.9 134.9 134.9 133.9
Bladder 141.3 138.1 139.7 138.1 138.6 139.7
Head and PTV 213.0 207.1 207.1 207.1 207.1 207.1
neck Spinal cord 123.3 125.7 124.7 123.6 122.1 124.2
C-shape Central core 55.6 53.6 52.9 53.5 52.9 52.9
Outer target 207.9 212.3 212.3 211.7 211.7 212.3
VMAT
Multitarget 50 Gy target 218.6 218.9 218.9 218.9 219.4 218.9
25 Gy target 107.8 107.6 108.1 108.1 108.1 108.1
12.5 Gy target 56.2 53.8 53.3 53.8 53.8 53.8
Prostate PTV 185.3 184.1 184.1 184.1 184.6 184.6
Rectum 143.2 144.4 143.8 144.4 143.8 143.8
Bladder 136.7 128.1 129.7 129.2 129.7 130.2
Head and PTV 206.2 198.2 197.7 198.2 198.2 197.7
neck Spinal cord 133.9 127.8 127.8 126.8 126.2 128.3
C-shape Central core 47.8 44.2 43.7 43.7 44.2 44.2
Outer target 207.7 202.4 202.4 202.4 200.8 201.9
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Table 3.3: Point dose measurements: Percent difference. The percent differences are given
for all five measurements taken at each point discussed in Table 2.9. The calculated dose at
each point is included for reference.
Plan Point description Calculated Percent differences (%)
dose (cGy)
IMRT
Multitarget 50 Gy target 214.7 −0.51 −0.51 −0.25 −0.25 −0.51
25 Gy target 121.7 −1.03 −1.29 −1.81 −2.07 −1.81
12.5 Gy target 64.2 −2.06 −2.06 −2.06 −2.32 −2.58
Prostate PTV 184.0 −0.81 −0.81 −0.81 −0.52 −0.81
Rectum 132.9 0.84 0.55 1.14 1.14 0.55
Bladder 141.3 −1.79 −0.92 −1.79 −1.50 −0.92
Head and PTV 213.0 −2.95 −2.95 −2.95 −2.95 −2.95
neck Spinal cord 123.3 1.21 0.69 0.17 −0.61 0.43
C-shape Central core 55.6 −1.00 −1.33 −1.07 −1.33 −1.33
Outer target 207.9 2.18 2.18 1.92 1.92 2.18
VMAT
Multitarget 50 Gy target 218.6 0.15 0.15 0.15 0.42 0.15
25 Gy target 107.8 −0.09 0.17 0.17 0.17 0.17
12.5 Gy target 56.2 −1.19 −1.45 −1.19 −1.19 −1.19
Prostate PTV 185.3 −0.66 −0.66 −0.66 −0.37 −0.37
Rectum 143.2 0.64 0.35 0.64 0.35 0.35
Bladder 136.7 −4.75 −3.88 −4.17 −3.88 −3.59
Head and PTV 206.2 −3.98 −4.24 −3.98 −3.98 −4.24
neck Spinal cord 133.9 −3.05 −3.05 −3.57 −3.83 −2.78
C-shape Central core 47.8 −1.79 −2.05 −2.05 −1.79 −1.79
Outer target 207.7 −2.65 −2.65 −2.65 −3.43 −2.91
differences of each measurement, using the method described in Sec. 2.4.1.
Table 3.4 lists the means and standard deviations of the dose values and percent
differences for each point. A Wilcoxon rank-sum test was performed for each point
comparing the IMRT and VMAT percent difference results, the results of which are also
displayed in Table 3.4. The five measurements at any given point generally exhibited a
small spread of values, leading to the rank-sum test indicating significance (p < 0.05) for
the majority of comparisons.
61
Table 3.4: Point dose measurements aggregated by point. For each point, the means and standard deviations of the dose values
and the percent differences are shown, as well as the result of a Wilcoxon rank-sum test comparing the IMRT and VMAT
results. The calculated point doses are also included for reference.
Point description Calculated Mean dose (cGy) Mean % diff Wilcoxon
dose (cGy) ± St. Dev. ± St. Dev. rank-sum test p
Multitarget IMRT VMAT IMRT VMAT IMRT VMAT
50 Gy target 214.7 218.6 213.9 ± 0.3 219.0 ± 0.2 −0.40 ± 0.14 0.21 ± 0.12 0.0079
25 Gy target 121.7 107.8 118.5 ± 0.9 108.0 ± 0.2 −1.60 ± 0.43 0.12 ± 0.12 0.0079
12.5 Gy target 64.2 56.2 59.8 ± 0.5 53.7 ± 0.2 −2.22 ± 0.23 −1.25 ± 0.12 0.0079
Prostate
PTV 184.0 185.3 182.6 ± 0.2 184.3 ± 0.3 −0.75 ± 0.13 −0.55 ± 0.16 0.032
Rectum 132.9 143.2 134.4 ± 0.5 144.0 ± 0.3 0.84 ± 0.29 0.47 ± 0.16 0.063
Bladder 141.3 136.7 138.8 ± 0.8 129.4 ± 0.8 −1.38 ± 0.44 −4.06 ± 0.44 0.0079
Head and neck
PTV 213.0 206.2 207.1 ± 0.0 198.0 ± 0.3 −2.95 ± 0.00 −4.09 ± 0.14 0.0079
Spinal cord 123.3 133.9 124.1 ± 1.4 127.4 ± 0.9 0.38 ± 0.68 −3.25 ± 0.43 0.0079
C-shape
Central core 55.6 47.8 53.2 ± 0.3 44.0 ± 0.3 −1.22 ± 0.16 −1.89 ± 0.14 0.0079
Outer target 207.9 207.7 212.0 ± 0.3 202.0 ± 0.7 2.07 ± 0.14 −2.86 ± 0.34 0.0079
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Table 3.5: Point dose measurements aggregated by modality. The reported means and
standard deviations were calculated using the mean values shown in Table 3.4. Also
included is the result of a Wilcoxon rank-sum test comparing the IMRT and VMAT results.
Mean % difference
± St. Dev. Wilcoxon rank-sum test p
IMRT VMAT
−0.72 ± 1.50 −1.71 ± 1.77 0.27
Table 3.6: Film gamma calculation results. Gamma analysis was performed using criteria
of 3% and 3 mm. The percent of pixels with gamma less than one was reported for each
measurement. The results for each of the three films irradiated by each treatment and in
each film orientation are given here.
Plan Film orientation % pixels passing γ, criteria=3%/3 mm
IMRT VMAT
Multitarget Coronal 98.68 99.51 99.50 98.89 98.99 99.11
Prostate 99.96 99.99 99.98 100.00 99.97 100.00
Neck 99.07 99.28 99.00 98.00 97.55 97.53
C-shape 98.88 99.41 99.57 99.93 99.89 99.94
Multitarget Sagittal 98.08 98.74 99.18 98.68 99.45 99.00
Prostate 99.05 99.23 98.50 99.98 100.00 99.97
Neck 96.14 97.07 96.34 98.33 98.28 98.33
C-shape 99.64 99.22 98.92 99.40 98.71 97.63
Table 3.5 lists the means and standard deviations of the results from Table 3.4, aggregated
by modality. The result of a Wilcoxon rank-sum test is also displayed. The difference
between the IMRT and VMAT point dose results was not statistically significant (p > 0.05).
3.3 Film Results
For each plan and film orientation (coronal and sagittal), three films were irradiated and
analyzed. Each film was compared to a calculated planar dose distribution from Pinnacle3
using gamma analysis with criteria of 3%/3 mm, and the percent of pixels with gamma
less than one was calculated. Table 3.6 reports the percent of pixels passing for each film
63
Table 3.7: Film gamma results aggregated by treatment setup. The mean percent of pixels
passing for each setup is shown with its standard deviation.
Plan and film orientation Mean % of pixels
passing ± St. Dev.
Multitarget IMRT VMAT
Coronal 99.23 ± 0.48 99.00 ± 0.11
Sagittal 98.67 ± 0.55 99.04 ± 0.39
Prostate
Coronal 99.98 ± 0.02 99.99 ± 0.02
Sagittal 98.93 ± 0.38 99.98 ± 0.02
Head and neck
Coronal 99.12 ± 0.15 97.69 ± 0.27
Sagittal 96.52 ± 0.49 98.31 ± 0.03
C-shape
Coronal 99.29 ± 0.36 99.92 ± 0.03
Sagittal 99.26 ± 0.36 98.58 ± 0.89
analysis. The mean and standard deviation of all the films from each treatment setup are
shown in Table 3.7. Like the point dose results, the film results showed little variation
between films from the same treatment setup. No statistical tests were performed on
the site-specific film data because the Wilcoxon rank-sum test lacked sufficient statistical
power for the given sample size to distinguish significant differences at the 5% level.
Table 3.8 lists the means and standard deviations found from the means listed in
Table 3.7, aggregated by the two modalities, including the result of the Wilcoxon rank-sum
test. The difference between the IMRT and VMAT results was not significant (p > 0.05).
Figures 3.9–3.12 show representative gamma distributions for each of the structure
sets, modalities, and orientations. The other film results were similar to these results (see
Appendix A).
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Figure 3.9: Representative gamma results for the multitarget film data. (a) and (b) are
the coronal measurements for IMRT and VMAT, respectively; (c) and (d) are the sagittal
measurements for IMRT and VMAT, respectively.
65
X distance [cm]
Y 
di
sta
nc
e [
cm
]
Gamma values. PTV Threshold= 10%
Criteria: dosedi=3%, DTA=3 mm
% passing=100.0%
Measured distribution shown where gamma passes
Measured le name: prost−imrt−cor−1−meas.mat
 
 
2.5 5 7.5 10
2.5
5
7.5
10
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
X distance [cm]
Y 
di
sta
nc
e [
cm
]
Gamma values. PTV Threshold= 10%
Criteria: dosedi=3%, DTA=3 mm
% passing=100.0%
Measured distribution shown where gamma passes
Measured le name: prost−vmat−cor−1−meas.mat
 
 
2.5 5 7.5 10 12.5
2.5
5
7.5
10
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
X distance [cm]
Y 
di
sta
nc
e [
cm
]
Gamma values. PTV Threshold= 10%
Criteria: dosedi=3%, DTA=3 mm
% passing=99.1%
Measured distribution shown where gamma passes
Measured le name: prost−imrt−sag−1−meas.mat
 
 
2.5 5 7.5 10 12.5
2.5
5
7.5
10
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
X distance [cm]
Y 
di
sta
nc
e [
cm
]
Gamma values. PTV Threshold= 10%
Criteria: dosedi=3%, DTA=3 mm
% passing=100.0%
Measured distribution shown where gamma passes
Measured le name: prost−vmat−sag−1−meas.mat
 
 
2.5 5 7.5 10 12.5
2.5
5
7.5
10
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
(a) (b)
(d)(c)
Figure 3.10: Representative gamma results for the prostate film data. (a) and (b) are
the coronal measurements for IMRT and VMAT, respectively; (c) and (d) are the sagittal
measurements for IMRT and VMAT, respectively.
66
X distance [cm]
Y 
di
sta
nc
e [
cm
]
Gamma values. PTV Threshold= 10%
Criteria: dosedi=3%, DTA=3 mm
% passing=99.1%
Measured distribution shown where gamma passes
Measured le name: neck−imrt−cor−1−meas.mat
 
 
2.5 5 7.5 10 12.5 15 17.5
2.5
5
7.5
10
12.5
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
X distance [cm]
Y 
di
sta
nc
e [
cm
]
Gamma values. PTV Threshold= 10%
Criteria: dosedi=3%, DTA=3 mm
% passing=98.0%
Measured distribution shown where gamma passes
Measured le name: neck−vmat−cor−1−meas.mat
 
 
2.5 5 7.5 10 12.5 15
2.5
5
7.5
10
12.5
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
X distance [cm]
Y 
di
sta
nc
e [
cm
]
Gamma values. PTV Threshold= 10%
Criteria: dosedi=3%, DTA=3 mm
% passing=96.1%
Measured distribution shown where gamma passes
Measured le name: neck−imrt−sag−1−meas.mat
 
 
2.5 5 7.5 10 12.5 15 17.5
2.5
5
7.5
10
12.5
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
X distance [cm]
Y 
di
sta
nc
e [
cm
]
Gamma values. PTV Threshold= 10%
Criteria: dosedi=3%, DTA=3 mm
% passing=98.3%
Measured distribution shown where gamma passes
Measured le name: neck−vmat−sag−1−meas.mat
 
 
2.5 5 7.5 10 12.5 15
2.5
5
7.5
10
12.5
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
(a) (b)
(d)(c)
Figure 3.11: Representative gamma results for the head and neck film data. (a) and (b) are
the coronal measurements for IMRT and VMAT, respectively; (c) and (d) are the sagittal
measurements for IMRT and VMAT, respectively.
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Figure 3.12: Representative gamma results for the C-shape film data. (a) and (b) are
the coronal measurements for IMRT and VMAT, respectively; (c) and (d) are the sagittal
measurements for IMRT and VMAT, respectively.
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Table 3.8: Film gamma results aggregated by modality. The reported means and standard
deviations were calculated using the mean values shown in Table 3.7. Also included is the
result of a Wilcoxon rank-sum test comparing the IMRT and VMAT results.
Mean % of pixels
passing ± St. Dev. Wilcoxon rank-sum test p
IMRT VMAT
98.87 ± 1.02 99.07 ± 0.85 1.00
Table 3.9: MapCHECK gamma calculation results. Gamma analysis was performed using
criteria of 3% and 3 mm. The percent of diode measurements with gamma less than one
was reported. The results for each of the five MapCHECK measurements irradiated by
each treatment are given here.
Plan % diodes passing
γ criteria=3%/3 mm
IMRT
Multitarget 99.39 99.39 99.39 99.39 99.39
Prostate 98.71 98.71 98.71 98.71 98.71
Head and neck 98.47 98.85 98.47 98.47 98.09
C-shape 98.87 97.74 98.50 97.74 97.74
VMAT
Multitarget 98.70 98.37 98.70 98.37 99.02
Prostate 100.00 99.59 99.59 99.59 99.59
Head and neck 98.21 98.21 98.57 98.57 98.21
C-shape 97.86 97.86 97.51 97.86 97.51
3.4 MapCHECK Results
Each treatment plan was delivered five times to the MapCHECK device. The recorded
distribution was analyzed in the MapCHECK software using gamma analysis with criteria
of 3%/3 mm. Each measurement was compared to the calculated planar dose distribution
from Pinnacle3. The percent of diode measurements passing gamma is reported for each
MapCHECK measurement in Table 3.9. Each treatment type was aggregated and the means
and standard deviations are listed in Table 3.10, with the results of Wilcoxon rank-sum
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Table 3.10: MapCHECK gamma results aggregated by treatment. The mean percent of
diodes passing for each treatment is shown with its standard deviation, along with a
Wilcoxon rank-sum test comparing the IMRT and VMAT results.
Plan Mean % of diodes Wilcoxon
passing ± St. Dev. rank-sum test p
IMRT VMAT
Multitarget 99.39 ± 0.00 98.63 ± 0.27 0.0079
Prostate 98.71 ± 0.00 99.67 ± 0.19 0.0079
Head and neck 98.47 ± 0.27 98.35 ± 0.20 0.77
C-shape 98.12 ± 0.53 97.72 ± 0.19 0.57
Table 3.11: MapCHECK gamma results aggregated by modality. The reported means and
standard deviations were calculated using the mean values shown in Table 3.10. Also
included is the result of a Wilcoxon rank-sum test comparing the IMRT and VMAT results.
Mean % of diodes
passing ± St. Dev. Wilcoxon rank-sum test p
IMRT VMAT
98.67 ± 0.54 98.59 ± 0.81 0.89
tests comparing the VMAT and IMRT results. The head and neck and C-shape differences
were not significant (p > 0.05), and the prostate and multitarget differences were (p < 0.05).
Similar to the film and point dose results, the MapCHECK results showed little variation
between measurements. Table 3.11 contains the means and standard deviations of the
mean IMRT and VMAT results listed in Table 3.10, aggregated for each treatment modality,
along with the result of the Wilcoxon rank-sum test. The difference between modalities
was not significant (p > 0.05).
Figures 3.13–3.20 are representative results from the MapCHECK measurements for
each structure set and modality, as output by the MapCHECK software. The other
MapCHECK results were similar to these results (see Appendix B).
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C:\SNC\Patient Plans\Mancuso~Thesi...\MapCHECK_multi-imrt-1(Mancuso,Thesis).txt C:\SNC\Patient Plans\Manc...\TPS_Map-Multi-IMRT-1mm - Copy (2)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 329
 : 327
 : 2
 : 99.4
Dose Values in cGy
Cax Normal Picked
Set1 267.28 266.68 267.28
Set2 265.31 265.57 265.31
Set1-Set2 1.97 1.11 1.97
% Diff 0.74 0.42 0.74
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 1,0
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure 3.13: Representative MapCHECK output for a multitarget IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~The...\MapCHECK_multi-vmat-1(Mancuso,Thesis).txt C:\SNC\Patient Plans\Man...\TPS_Map-Multi-VMAT-1mm - Copy (2)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 307
 : 303
 : 4
 : 98.7
Dose Values in cGy
Cax Normal Picked
Set1 277.39 287.70 277.39
Set2 273.32 279.43 273.32
Set1-Set2 4.07 8.26 4.07
% Diff 1.46 2.96 1.46
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -2,0
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure 3.14: Representative MapCHECK output for a multitarget VMAT delivery.
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C:\SNC\Patient Plans\Mancuso~Thesi...\MapCHECK_prost-imrt-1(Mancuso,Thesis).txt C:\SNC\Patient Plans\Manc...\TPS_Map-Prost-IMRT-1mm - Copy (2)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 232
 : 229
 : 3
 : 98.7
Dose Values in cGy
Cax Normal Picked
Set1 225.18 231.21 225.18
Set2 224.69 229.22 224.69
Set1-Set2 0.49 1.99 0.49
% Diff 0.21 0.87 0.21
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -4,0
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure 3.15: Representative MapCHECK output for a prostate IMRT delivery.
73
C:\SNC\Patient Plans\Mancuso~The...\MapCHECK_prost-vmat-1(Mancuso,Thesis).txt C:\SNC\Patient Plans\Man...\TPS_Map-Prost-VMAT-1mm - Copy (2)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 241
 : 241
 : 0
 : 100
Dose Values in cGy
Cax Normal Picked
Set1 221.65 220.20 221.65
Set2 218.03 213.47 218.03
Set1-Set2 3.62 6.73 3.62
% Diff 1.70 3.15 1.70
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -4.5,0.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure 3.16: Representative MapCHECK output for a prostate VMAT delivery.
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C:\SNC\Patient Plans\Mancuso~Thes...\MapCHECK_neck-imrt-1(Mancuso,Thesis).txt C:\SNC\Patient Plans\Man...\TPS_Map-Neck-IMRT-1mm - Copy (2)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 262
 : 258
 : 4
 : 98.5
Dose Values in cGy
Cax Normal Picked
Set1 258.75 345.33 258.75
Set2 266.11 335.23 266.11
Set1-Set2 -7.36 10.10 -7.36
% Diff -2.20 3.01 -2.20
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 1.5,-2.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure 3.17: Representative MapCHECK output for a head and neck IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~Th...\MapCHECK_neck-vmat-1(Mancuso,Thesis).txt C:\SNC\Patient Plans\Man...\TPS_Map-Neck-VMAT-1mm - Copy (2)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 279
 : 274
 : 5
 : 98.2
Dose Values in cGy
Cax Normal Picked
Set1 255.15 310.14 255.15
Set2 265.47 323.00 265.47
Set1-Set2 -10.32 -12.86 -10.32
% Diff -3.20 -3.98 -3.20
DTA(mm) 0.00 3.61 0.00
0,0Coords
(y,x) cm
0,0 1,-3
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure 3.18: Representative MapCHECK output for a head and neck VMAT delivery.
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C:\SNC\Patient Plans\Mancuso~The...\MapCHECK_ceasy-imrt-1(Mancuso,Thesis).txt C:\SNC\Patient Plans\Man...\TPS_Map-CEasy-IMRT-1mm - Copy (2)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 266
 : 263
 : 3
 : 98.9
Dose Values in cGy
Cax Normal Picked
Set1 52.86 287.50 52.86
Set2 48.66 293.13 48.66
Set1-Set2 4.20 -5.63 4.20
% Diff 1.43 -1.92 1.43
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 3.5,-2.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure 3.19: Representative MapCHECK output for a C-shape IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~Th...\MapCHECK_ceasy-vmat-1(Mancuso,Thesis).txt C:\SNC\Patient Plans\Ma...\TPS_Map-CEasy-VMAT-1mm - Copy (2)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 281
 : 275
 : 6
 : 97.9
Dose Values in cGy
Cax Normal Picked
Set1 45.88 303.25 45.88
Set2 43.38 293.80 43.38
Set1-Set2 2.49 9.45 2.49
% Diff 0.85 3.22 0.85
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -4.5,2.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 2 0
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure 3.20: Representative MapCHECK output for a C-shape VMAT delivery.
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3.5 Data Summary
For all three types of measurements, the global comparisons between IMRT and VMAT
QA results showed statistically insignificant differences (p > 0.05).
For site-specific point dose measurements, IMRT QA showed significantly better
agreement in five cases, VMAT QA showed significantly better agreement in four cases,
and VMAT showed insignificantly better agreement in one case. For site-specific diode
array measurements, IMRT QA showed significantly better agreement in one case, VMAT
QA showed significantly better agreement in one case, and IMRT showed insignificantly
better agreement in two cases. In sum, IMRT QA showed statistically better agreement in
six cases, VMAT QA showed statistically better agreement in five cases, and three tested
cases gave statistically insignificant differences. For site-specific film measurements, IMRT
QA showed better agreement in three cases, and VMAT QA showed better agreement in
five. Statistical tests were not performed on the film site-specific cases.
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Chapter 4
Discussion
In this work, we performed a comprehensive investigation comparing VMAT and IMRT
patient specific QA using film, ion chamber, and 2D diode array measurements. Global
comparisons between IMRT and VMAT QA results showed no statistically significant
differences. The largest observed difference was in the point dose data, but even that
difference was not statistically significant (p > 0.05). The film and MapCHECK data
showed very little difference between the IMRT and VMAT QA results. These results
support the hypothesis that IMRT and VMAT QA results are not significantly different.
Although we did not observe significant differences between global IMRT and VMAT
QA results, we did observe statistically significant differences for some site-specific
measurements, as seen in Tables 3.4 and 3.10. However, if we further examine the number
of cases in which each modality had better agreement, we find that roughly half of the
data points demonstrated IMRT as having better agreement and roughly half showed
VMAT as having better agreement. This suggests that, while one modality may show
better agreement in specific cases, on the whole, neither IMRT nor VMAT QA shows better
agreement than the other.
One of the important concepts in this work is the idea of clinical significance. Statistical
significance is easily defined by choosing an appropriate significance level for a given
statistical test. Clinical significance, however, is a more subjective determination of whether
a difference has an impact on the day-to-day workings in the clinic. Clinical significance
may be present even if no statistical significance is found, and vice versa. This is important
because our data showed a difference between the IMRT and VMAT point dose means.
The result was not statistically significant (p > 0.05), but additional measurement locations
could possibly increase the statistical significance. However, the mean results of the
IMRT and VMAT point dose measurements differed by less than 1%, which is a small
80
value compared to the standard deviations of the measurements associated with the two
modalities. In addition to this, the typical action level for point dose measurements in
our clinic is a 3% difference, and can be even larger in the case of complex treatments.
Our measured mean IMRT and VMAT point dose measurements were well below this
3% level. This suggests that there was not a clinically significant difference between the
IMRT and VMAT point dose measurements. This same argument can be applied to the
film and diode array data, which showed even less of a difference between modalities than
the point dose data.
4.1 Comparison to Previous Work
As stated in the introduction, this work was the first comprehensive comparison of
IMRT QA and VMAT QA. Other investigators have performed QA on IMRT and VMAT
plans, but this work focused on verifying the repeatability of the measurements and on
standardizing the QA methods to be as similar as possible for each modality.
Jursinic, Sharma, and Reuter (2010) reported MapCHECK and MapPHAN passing
rates of 99.5% for a fixed-beam IMRT plan and 99.8% for RapidArc plans, using criteria of
3%/3 mm. These results are similar to our MapCHECK results of 98.67% and 98.59% for
IMRT and VMAT, respectively.
Masi et al. (2011) examined two different planning systems and several different mea-
surement devices for VMAT QA. The mean passing rates for 36 EBT2 film measurements
and 25 MapCHECK in MapPHAN measurements were 91.3% and 96.9%, respectively. The
passing rates in our study were higher than these, especially for the EBT2 QA. We may
attribute this to our method of digitization and normalization of the EBT2 film, which
differed from Masi et al, who used a flatbed scanner and absolute dose calibration for their
film. They also measured point doses using an Exradin A16 ion chamber for 50 VMAT
plans, and reported a mean point dose difference and standard deviation of 1.1% ± 1.0%.
The magnitude of this mean difference is similar to the mean dose difference of −1.71%
that we found in our study.
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Table 4.1: Individual institution point dose results from TG 119. Percent differences for
high and low dose locations reported by each institution are included, along with their
standard deviations.
Institution High dose High dose Low dose Low dose
mean (%) St. Dev. (%) mean (%) St. Dev. (%)
A −0.4 2.3 −0.6 0.7
B −1.2 2.1 −1.0 1.8
C −0.6 1.1 0.6 3.4
D −0.7 0.4 1.3 0.6
E −1.7 1.4 −0.5 1.3
F 0.2 1.2 n/a n/a
G −1.3 4.4 −0.5 0.5
H −1.4 0.4 0.8 2.4
I −0.9 3.0 −0.8 1.4
J 0.8 1.9 4.5 2.1
The TG 119 results were reported in Table 1.1 (Ezzell et al. 2009). We noticed a few
differences when comparing our results to the TG 119 results. First, the mean point dose
differences we found for IMRT and VMAT were both somewhat less than zero (−0.72%
and −1.71% for IMRT and VMAT, respectively), while the mean point dose differences
from TG 119 were nearer zero (−0.2% and 0.3% for high and low dose points, respectively).
This may be explained by examining the individual institution results shown in the TG 119
report (see Table 4.1). Some institutions showed mean point dose results above or below
zero, similar to ours. However, when results from all the institutions were averaged
together, the mean difference converged to zero. Moreover, the standard deviations of our
point dose results (1.50% and 1.77% for IMRT and VMAT, respectively) were similar to the
standard deviations reported by other institutions. Thus, we conclude that our point dose
results are consistent with those of the TG 119 institutions.
Second, our film results and diode array results had higher passing rates and smaller
standard deviations than the TG 119 composite film results. We observed passing rates
of 98.9% ± 1.0% and 99.1% ± 0.8% for IMRT and VMAT film results, and 98.7% ± 0.5%
and 98.6% ± 0.8% for IMRT and VMAT MapCHECK results, while the mean composite
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Table 4.2: Individual institution composite film results from TG 119. The mean percent of
pixels passing gamma using 3%/3 mm criteria is reported for each institution that took
composite film measurements. The standard deviation reported by each institution is also
shown.
Institution Mean % St. Dev.
passing γ
A 99.5 0.4
B 92.6 4.3
D 99.9 0.3
E 97.6 2.3
F 98.0 1.1
G 93.0 6.5
I 95.8 3.6
J 97.5 2.9
film passing rate from TG 119 was 96.3% ± 4.4%. Like the point dose results, our results
exhibited characteristics similar to the film results reported by individual institutions in
TG 119 (see Table 4.2).
4.2 Possible Limitations of the Work
There were some limitations in this work, which are discussed here. One limitation of
this work was that it focused on one specific institution’s implementations of IMRT and
VMAT. It is possible that other institutions may find larger differences between IMRT and
VMAT QA (Kisling 2010). However, the results found here show that it is reasonable for
IMRT and VMAT QA to give comparable results. Further work by other institutions may
increase the confidence of this assessment.
Another limitation arises from the finite size of the ion chamber used for point dose
measurements. The A1SL ion chamber has a volume of 0.057 cc, which corresponds to
dimensions of roughly 4 mm on a side. This is a non-negligible size when striving for
millimeter placement accuracy. To investigate the potential effect of volume averaging,
planar dose files were exported from Pinnacle3 at the locations of the different dose points,
in both coronal and sagittal orientations. We examined the area surrounding the point
dose measurement locations to observe the approximate dose gradients. In high dose, low
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gradient regions, the observed dose gradients were on the order of 1 cGy/mm. However,
in the lower dose regions (specifically, at the points in the OAR structures), dose gradients
of 3–5 cGy/mm were observed. These gradients are significant, and mean that different
parts of the chamber likely received significantly different doses when measuring those
point doses.
These significant dose gradients also have the potential to cause larger dose errors in
the associated point dose measurements, because very small positional errors can cause
large dose differences. Table 3.4 shows that the standard deviations for some of the low
dose points were larger than the standard deviations for the high dose points, which could
be due to the higher dose gradient at those points. However, the standard deviations were
still much smaller than the observed dose gradients of 3–5 cGy/mm, which indicates that
the inter-measurement ion chamber placement positional error was less than 1 mm. This
indicates a high precision of ion chamber placement. However, the high dose gradient
might still be responsible for the lower agreement seen in some of the low dose points if
there were systematic errors in the placement of the chamber.
One other possible limitation may have been a systematic shift seen in the film data
when compared to the exported planar dose data. This shift can be seen in Fig. 4.1. Looking
at the dose profiles for these film measurements, a 1–2 mm shift in the y-direction can
be seen. This may suggest a limitation in the registration procedure for the irradiated
films. A similar shift was observed in almost every film analyzed. We investigated several
possible causes for this shift, but did not find a source of the error. One possible remaining
explanation is that the shift was due to the CT scan slice size. The CT scan of the cylindrical
phantom was taken with a 2.5 mm slice size. The center of the cylindrical phantom is
defined by a set of intersecting lines machined onto the phantom (see Fig. 2.6). To indicate
the location of the center line on the CT scan, three radiopaque markers were placed on the
cylindrical phantom before the CT scan. These markers were visible on the CT scan and
indicated the location of the isocenter. Since these markers could be located anywhere in
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Figure 4.1: Vertical film profiles displaying a systematic shift. In each of these cases, a
systematic 1–2 mm shift can be seen between the film (dotted line) and the exported planar
dose data (solid line).
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the 2.5 mm slice in which they appeared, there is no guarantee that the isocenter defined in
Pinnacle3 is at the exact same location as the actual isocenter of the phantom. This could be
the source of the systematic shift in the longitudinal direction. Further testing, including
repeating the CT scan of the cylindrical phantom, may be able to verify whether this was
the cause of the systematic shift. Regardless of the cause, this shift was seen in almost all
film measurements, and so would have a similar effect on both IMRT and VMAT data, and
thus should not affect the comparisons.
4.2.1 Normality
One method to increase the power of the statistical tests would be to use a Student’s
t-test instead of a Wilcoxon rank-sum test. The rank-sum test does not assume normality
of the underlying data, while the t-test does. This assumption gives the t-test more power
to determine significance. However, if the assumption is false, then the additional power
is not justified. To investigate the possibility of using the t-test, histograms were created to
assess the normality of the data.
Two different kinds of histograms were constructed to investigate normality of the
data for the two different statistical comparisons that were made (see Sec. 2.4.5). To
investigate the normality of the data for the site-specific comparisons, the measured data
was first transformed by subtracting the mean value of the site from each measurement.
For an example, see Table 4.3. Here are listed the five MapCHECK measurements for the
Table 4.3: Site-specific normality check: Data transformation. For each set of repeated
measurements, the mean of the set was subtracted from each measurement. This is an
example transformation for the C-shape IMRT MapCHECK data.
% diodes passing Mean Measurement
γ criteria=3%/3 mm minus mean
98.87
98.12
0.75
97.74 −0.38
98.50 0.38
97.74 −0.38
97.74 −0.38
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Figure 4.2: Normality histograms. Plots (a–c) are histograms of data with the site-specific
means subtracted, and plots (d–f) are histograms of site-specific means. Plots (a–c) are IMRT
point dose, VMAT film, and combined IMRT and VMAT MapCHECK data, respectively;
plots (d–f) are combined data for point dose, film, and MapCHECK measurements,
respectively. In each plot, a Gaussian line with mean and standard deviation equal to the
given data is plotted for comparison.
C-shape IMRT delivery. The mean of these five measurements was subtracted from each
measurement. The purpose was to isolate the values that represent the inter-measurement
variations. This process was repeated for every measurement for each measurement type,
and the results were plotted in histograms for each measurement type and modality.
To investigate the normality of the data for global comparisons, the mean results of the
repeated measurements for each measurement setup were plotted in histograms.
Some of the histograms created are displayed in Fig. 4.2. Based on these results and other
similar plots (not shown), we decided that we could not conclude a normal underlying
distribution. While some plots suggested possible normality, others did not, and there
did not seem to be enough data points to confidently conclude that the data was normally
distributed. As such, we chose to use the Wilcoxon rank-sum test. While this resulted in a
87
less powerful statistical test, we are confident that we did not violate any assumptions of
the test.
4.3 Further Work
This work focused on using a standard set of geometries that has previously been used
and given credence by AAPM TG 119. In order to ensure reproducibility of the data, each
measurement was taken several times. A further study could be conducted that includes
more plans (but perhaps with fewer measurements per plan), especially clinical plans.
This would give more data points for the statistical tests comparing VMAT and IMRT
data. However, it must be remembered that differences, even if found to be statistically
significant, may not carry clinical significance if they are small. If this further work were
performed at another institution and showed results similar to ours, it would increase our
confidence further that there is no clinical difference between IMRT and VMAT QA.
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Chapter 5
Conclusion
In this study, we investigated differences between fixed-beam IMRT and VMAT patient
specific QA. IMRT and VMAT plans were constructed for four structure set geometries
provided in AAPM Task Group Report 119, viz.: multitarget, mock prostate, mock head and
neck, and C-shape. The plans were delivered by a linear accelerator to phantom geometries,
and the resulting dose distribution was measured using ion chamber, radiochromic
film, and a 2D diode array. Each measurement was repeated several times to verify
reproducibility of the results. The average percent differences between measured and
calculated point doses were less than 2% for both IMRT and VMAT treatments, and both
film and diode array measurements yielded averages of better than 98% of pixels/diodes
passing the gamma test for both IMRT and VMAT treatments.
Statistical analysis of the aggregate IMRT and VMAT QA results showed no statistically
significant differences between the two delivery techniques. These results suggest that it is
appropriate to apply IMRT QA methods and action levels to VMAT QA.
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Appendix A
Film Images
This appendix includes the remaining film images not shown in Sec. 3.3. The film images
shown there consisted of the first film images for each unique combination of geometry,
modality, and plane. The following images are the second and third such images.
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Figure A.1: Second set of gamma results for the multitarget film data. (a) and (b) are
the coronal measurements for IMRT and VMAT, respectively; (c) and (d) are the sagittal
measurements for IMRT and VMAT, respectively.
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Figure A.2: Second set of gamma results for the prostate film data. (a) and (b) are the
coronal measurements for IMRT and VMAT, respectively; (c) and (d) are the sagittal
measurements for IMRT and VMAT, respectively.
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Figure A.3: Second set of gamma results for the head and neck film data. (a) and (b) are
the coronal measurements for IMRT and VMAT, respectively; (c) and (d) are the sagittal
measurements for IMRT and VMAT, respectively.
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Figure A.4: Second set of gamma results for the C-shape film data. (a) and (b) are the
coronal measurements for IMRT and VMAT, respectively; (c) and (d) are the sagittal
measurements for IMRT and VMAT, respectively.
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Figure A.5: Third set of gamma results for the multitarget film data. (a) and (b) are
the coronal measurements for IMRT and VMAT, respectively; (c) and (d) are the sagittal
measurements for IMRT and VMAT, respectively.
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Figure A.6: Third set of gamma results for the prostate film data. (a) and (b) are the coronal
measurements for IMRT and VMAT, respectively; (c) and (d) are the sagittal measurements
for IMRT and VMAT, respectively.
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Figure A.7: Third set of gamma results for the head and neck film data. (a) and (b) are
the coronal measurements for IMRT and VMAT, respectively; (c) and (d) are the sagittal
measurements for IMRT and VMAT, respectively.
101
X distance [cm]
Y 
di
sta
nc
e [
cm
]
Gamma values. PTV Threshold= 10%
Criteria: dosedi=3%, DTA=3 mm
% passing=99.6%
Measured distribution shown where gamma passes
Measured le name: ceasy−imrt−cor−3−meas.mat
 
 
2.5 5 7.5 10 12.5
2.5
5
7.5
10
12.5
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
X distance [cm]
Y 
di
sta
nc
e [
cm
]
Gamma values. PTV Threshold= 10%
Criteria: dosedi=3%, DTA=3 mm
% passing=99.9%
Measured distribution shown where gamma passes
Measured le name: ceasy−vmat−cor−3−meas.mat
 
 
2.5 5 7.5 10 12.5
2.5
5
7.5
10
12.5
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
X distance [cm]
Y 
di
sta
nc
e [
cm
]
Gamma values. PTV Threshold= 10%
Criteria: dosedi=3%, DTA=3 mm
% passing=98.9%
Measured distribution shown where gamma passes
Measured le name: ceasy−imrt−sag−3−meas.mat
 
 
2.5 5 7.5 10 12.5 15
2.5
5
7.5
10
12.5
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
X distance [cm]
Y 
di
sta
nc
e [
cm
]
Gamma values. PTV Threshold= 10%
Criteria: dosedi=3%, DTA=3 mm
% passing=97.6%
Measured distribution shown where gamma passes
Measured le name: ceasy−vmat−sag−3−meas.mat
 
 
2.5 5 7.5 10 12.5 15
2.5
5
7.5
10
12.5
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
(a) (b)
(d)(c)
Figure A.8: Third set of gamma results for the C-shape film data. (a) and (b) are the coronal
measurements for IMRT and VMAT, respectively; (c) and (d) are the sagittal measurements
for IMRT and VMAT, respectively.
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Appendix B
MapCHECK Images
This appendix includes the remaining MapCHECK images not shown in Sec. 3.4. The
images shown there were the first MapCHECK output images for each unique combination
of geometry and modality. The following images are the second through fifth such images.
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C:\SNC\Patient Plans\Mancuso~Thesi...\MapCHECK_multi-imrt-2(Mancuso,Thesis).txt C:\SNC\Patient Plans\Manc...\TPS_Map-Multi-IMRT-1mm - Copy (3)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 329
 : 327
 : 2
 : 99.4
Dose Values in cGy
Cax Normal Picked
Set1 269.41 267.91 269.41
Set2 265.31 265.57 265.31
Set1-Set2 4.10 2.34 4.10
% Diff 1.54 0.88 1.54
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 1,0
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.1: Second MapCHECK result for the multitarget IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~The...\MapCHECK_multi-vmat-2(Mancuso,Thesis).txt C:\SNC\Patient Plans\Man...\TPS_Map-Multi-VMAT-1mm - Copy (3)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 307
 : 302
 : 5
 : 98.4
Dose Values in cGy
Cax Normal Picked
Set1 277.93 287.71 277.93
Set2 273.32 279.43 273.32
Set1-Set2 4.60 8.27 4.60
% Diff 1.65 2.96 1.65
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -2,0
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.2: Second MapCHECK result for the multitarget VMAT delivery.
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C:\SNC\Patient Plans\Mancuso~Thesi...\MapCHECK_prost-imrt-2(Mancuso,Thesis).txt C:\SNC\Patient Plans\Manc...\TPS_Map-Prost-IMRT-1mm - Copy (3)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 232
 : 229
 : 3
 : 98.7
Dose Values in cGy
Cax Normal Picked
Set1 225.88 231.98 225.88
Set2 224.69 229.22 224.69
Set1-Set2 1.19 2.76 1.19
% Diff 0.52 1.20 0.52
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -4,0
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.3: Second MapCHECK result for the prostate IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~The...\MapCHECK_prost-vmat-2(Mancuso,Thesis).txt C:\SNC\Patient Plans\Man...\TPS_Map-Prost-VMAT-1mm - Copy (3)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 241
 : 240
 : 1
 : 99.6
Dose Values in cGy
Cax Normal Picked
Set1 221.62 220.60 221.62
Set2 218.03 213.47 218.03
Set1-Set2 3.59 7.13 3.59
% Diff 1.68 3.34 1.68
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -4.5,0.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.4: Second MapCHECK result for the prostate VMAT delivery.
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C:\SNC\Patient Plans\Mancuso~Thes...\MapCHECK_neck-imrt-2(Mancuso,Thesis).txt C:\SNC\Patient Plans\Man...\TPS_Map-Neck-IMRT-1mm - Copy (3)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 262
 : 259
 : 3
 : 98.9
Dose Values in cGy
Cax Normal Picked
Set1 257.87 345.95 257.87
Set2 266.11 335.23 266.11
Set1-Set2 -8.24 10.72 -8.24
% Diff -2.46 3.20 -2.46
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 1.5,-2.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.5: Second MapCHECK result for the head and neck IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~Th...\MapCHECK_neck-vmat-2(Mancuso,Thesis).txt C:\SNC\Patient Plans\Man...\TPS_Map-Neck-VMAT-1mm - Copy (3)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 279
 : 274
 : 5
 : 98.2
Dose Values in cGy
Cax Normal Picked
Set1 254.72 310.55 254.72
Set2 265.47 323.00 265.47
Set1-Set2 -10.75 -12.45 -10.75
% Diff -3.33 -3.85 -3.33
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 1,-3
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.6: Second MapCHECK result for the head and neck VMAT delivery.
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C:\SNC\Patient Plans\Mancuso~The...\MapCHECK_ceasy-imrt-2(Mancuso,Thesis).txt C:\SNC\Patient Plans\Man...\TPS_Map-CEasy-IMRT-1mm - Copy (3)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 266
 : 260
 : 6
 : 97.7
Dose Values in cGy
Cax Normal Picked
Set1 51.04 287.89 51.04
Set2 48.66 293.13 48.66
Set1-Set2 2.38 -5.25 2.38
% Diff 0.81 -1.79 0.81
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 3.5,-2.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.7: Second MapCHECK result for the C-shape IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~Th...\MapCHECK_ceasy-vmat-2(Mancuso,Thesis).txt C:\SNC\Patient Plans\Ma...\TPS_Map-CEasy-VMAT-1mm - Copy (3)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 281
 : 275
 : 6
 : 97.9
Dose Values in cGy
Cax Normal Picked
Set1 45.07 304.76 45.07
Set2 43.38 293.80 43.38
Set1-Set2 1.69 10.96 1.69
% Diff 0.58 3.73 0.58
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -4.5,2.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 2 0
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.8: Second MapCHECK result for the C-shape VMAT delivery.
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C:\SNC\Patient Plans\Mancuso~Thesi...\MapCHECK_multi-imrt-3(Mancuso,Thesis).txt C:\SNC\Patient Plans\Manc...\TPS_Map-Multi-IMRT-1mm - Copy (4)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 329
 : 327
 : 2
 : 99.4
Dose Values in cGy
Cax Normal Picked
Set1 267.80 268.12 267.80
Set2 265.31 265.57 265.31
Set1-Set2 2.49 2.55 2.49
% Diff 0.94 0.96 0.94
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 1,0
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.9: Third MapCHECK result for the multitarget IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~The...\MapCHECK_multi-vmat-3(Mancuso,Thesis).txt C:\SNC\Patient Plans\Man...\TPS_Map-Multi-VMAT-1mm - Copy (4)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 307
 : 303
 : 4
 : 98.7
Dose Values in cGy
Cax Normal Picked
Set1 278.45 289.24 278.45
Set2 273.32 279.43 273.32
Set1-Set2 5.12 9.81 5.12
% Diff 1.83 3.51 1.83
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -2,0
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.10: Third MapCHECK result for the multitarget VMAT delivery.
113
C:\SNC\Patient Plans\Mancuso~Thesi...\MapCHECK_prost-imrt-3(Mancuso,Thesis).txt C:\SNC\Patient Plans\Manc...\TPS_Map-Prost-IMRT-1mm - Copy (4)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 232
 : 229
 : 3
 : 98.7
Dose Values in cGy
Cax Normal Picked
Set1 225.45 232.21 225.45
Set2 224.69 229.22 224.69
Set1-Set2 0.75 2.98 0.75
% Diff 0.33 1.30 0.33
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -4,0
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.11: Third MapCHECK result for the prostate IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~The...\MapCHECK_prost-vmat-3(Mancuso,Thesis).txt C:\SNC\Patient Plans\Man...\TPS_Map-Prost-VMAT-1mm - Copy (4)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 241
 : 240
 : 1
 : 99.6
Dose Values in cGy
Cax Normal Picked
Set1 221.43 220.67 221.43
Set2 218.03 213.47 218.03
Set1-Set2 3.39 7.21 3.39
% Diff 1.59 3.38 1.59
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -4.5,0.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.12: Third MapCHECK result for the prostate VMAT delivery.
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C:\SNC\Patient Plans\Mancuso~Thes...\MapCHECK_neck-imrt-3(Mancuso,Thesis).txt C:\SNC\Patient Plans\Man...\TPS_Map-Neck-IMRT-1mm - Copy (4)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 262
 : 258
 : 4
 : 98.5
Dose Values in cGy
Cax Normal Picked
Set1 256.58 345.83 256.58
Set2 266.11 335.23 266.11
Set1-Set2 -9.53 10.59 -9.53
% Diff -2.84 3.16 -2.84
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 1.5,-2.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.13: Third MapCHECK result for the head and neck IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~Th...\MapCHECK_neck-vmat-3(Mancuso,Thesis).txt C:\SNC\Patient Plans\Man...\TPS_Map-Neck-VMAT-1mm - Copy (4)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 279
 : 275
 : 4
 : 98.6
Dose Values in cGy
Cax Normal Picked
Set1 254.48 310.70 254.48
Set2 265.47 323.00 265.47
Set1-Set2 -11.00 -12.30 -11.00
% Diff -3.40 -3.81 -3.40
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 1,-3
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.14: Third MapCHECK result for the head and neck VMAT delivery.
117
C:\SNC\Patient Plans\Mancuso~The...\MapCHECK_ceasy-imrt-3(Mancuso,Thesis).txt C:\SNC\Patient Plans\Man...\TPS_Map-CEasy-IMRT-1mm - Copy (4)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 266
 : 262
 : 4
 : 98.5
Dose Values in cGy
Cax Normal Picked
Set1 50.40 288.94 50.40
Set2 48.66 293.13 48.66
Set1-Set2 1.74 -4.19 1.74
% Diff 0.59 -1.43 0.59
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 3.5,-2.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.15: Third MapCHECK result for the C-shape IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~Th...\MapCHECK_ceasy-vmat-3(Mancuso,Thesis).txt C:\SNC\Patient Plans\Ma...\TPS_Map-CEasy-VMAT-1mm - Copy (4)(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 281
 : 274
 : 7
 : 97.5
Dose Values in cGy
Cax Normal Picked
Set1 45.07 303.80 45.07
Set2 43.38 293.80 43.38
Set1-Set2 1.69 10.01 1.69
% Diff 0.57 3.41 0.57
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -4.5,2.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 2 0
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.16: Third MapCHECK result for the C-shape VMAT delivery.
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C:\SNC\Patient Plans\Mancuso~Thesi...\MapCHECK_multi-imrt-4(Mancuso,Thesis).txt C:\SNC\Patient Plans\Mancuso...\TPS_Map-Multi-IMRT-1mm - Copy(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 329
 : 327
 : 2
 : 99.4
Dose Values in cGy
Cax Normal Picked
Set1 266.99 267.86 266.99
Set2 265.31 265.57 265.31
Set1-Set2 1.68 2.29 1.68
% Diff 0.63 0.86 0.63
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 1,0
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.17: Fourth MapCHECK result for the multitarget IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~The...\MapCHECK_multi-vmat-4(Mancuso,Thesis).txt C:\SNC\Patient Plans\Mancus...\TPS_Map-Multi-VMAT-1mm - Copy(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 307
 : 302
 : 5
 : 98.4
Dose Values in cGy
Cax Normal Picked
Set1 277.97 289.38 277.97
Set2 273.32 279.43 273.32
Set1-Set2 4.65 9.94 4.65
% Diff 1.66 3.56 1.66
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -2,0
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.18: Fourth MapCHECK result for the multitarget VMAT delivery.
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C:\SNC\Patient Plans\Mancuso~Thesi...\MapCHECK_prost-imrt-4(Mancuso,Thesis).txt C:\SNC\Patient Plans\Mancus...\TPS_Map-Prost-IMRT-1mm - Copy(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 232
 : 229
 : 3
 : 98.7
Dose Values in cGy
Cax Normal Picked
Set1 224.69 232.29 224.69
Set2 224.69 229.22 224.69
Set1-Set2 0.00 3.06 0.00
% Diff 0.00 1.34 0.00
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -4,0
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.19: Fourth MapCHECK result for the prostate IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~The...\MapCHECK_prost-vmat-4(Mancuso,Thesis).txt C:\SNC\Patient Plans\Mancus...\TPS_Map-Prost-VMAT-1mm - Copy(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 241
 : 240
 : 1
 : 99.6
Dose Values in cGy
Cax Normal Picked
Set1 221.69 220.92 221.69
Set2 218.03 213.47 218.03
Set1-Set2 3.66 7.46 3.66
% Diff 1.71 3.49 1.71
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -4.5,0.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.20: Fourth MapCHECK result for the prostate VMAT delivery.
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C:\SNC\Patient Plans\Mancuso~Thes...\MapCHECK_neck-imrt-4(Mancuso,Thesis).txt C:\SNC\Patient Plans\Mancus...\TPS_Map-Neck-IMRT-1mm - Copy(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 262
 : 258
 : 4
 : 98.5
Dose Values in cGy
Cax Normal Picked
Set1 256.43 345.56 256.43
Set2 266.11 335.23 266.11
Set1-Set2 -9.67 10.33 -9.67
% Diff -2.89 3.08 -2.89
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 1.5,-2.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.21: Fourth MapCHECK result for the head and neck IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~Th...\MapCHECK_neck-vmat-4(Mancuso,Thesis).txt C:\SNC\Patient Plans\Mancu...\TPS_Map-Neck-VMAT-1mm - Copy(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 279
 : 275
 : 4
 : 98.6
Dose Values in cGy
Cax Normal Picked
Set1 254.29 310.40 254.29
Set2 265.47 323.00 265.47
Set1-Set2 -11.18 -12.60 -11.18
% Diff -3.46 -3.90 -3.46
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 1,-3
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.22: Fourth MapCHECK result for the head and neck VMAT delivery.
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C:\SNC\Patient Plans\Mancuso~The...\MapCHECK_ceasy-imrt-4(Mancuso,Thesis).txt C:\SNC\Patient Plans\Mancu...\TPS_Map-CEasy-IMRT-1mm - Copy(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 266
 : 260
 : 6
 : 97.7
Dose Values in cGy
Cax Normal Picked
Set1 50.46 288.41 50.46
Set2 48.66 293.13 48.66
Set1-Set2 1.80 -4.72 1.80
% Diff 0.61 -1.61 0.61
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 3.5,-2.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.23: Fourth MapCHECK result for the C-shape IMRT delivery.
126
C:\SNC\Patient Plans\Mancuso~Th...\MapCHECK_ceasy-vmat-4(Mancuso,Thesis).txt C:\SNC\Patient Plans\Mancu...\TPS_Map-CEasy-VMAT-1mm - Copy(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 281
 : 275
 : 6
 : 97.9
Dose Values in cGy
Cax Normal Picked
Set1 45.04 303.11 45.04
Set2 43.38 293.80 43.38
Set1-Set2 1.66 9.31 1.66
% Diff 0.56 3.17 0.56
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -4.5,2.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 2 0
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.24: Fourth MapCHECK result for the C-shape VMAT delivery.
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C:\SNC\Patient Plans\Mancuso~Thesi...\MapCHECK_multi-imrt-5(Mancuso,Thesis).txt C:\SNC\Patient Plans\Mancuso~Thesi...\TPS_Map-Multi-IMRT-1mm(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 329
 : 327
 : 2
 : 99.4
Dose Values in cGy
Cax Normal Picked
Set1 267.38 268.58 267.38
Set2 265.31 265.57 265.31
Set1-Set2 2.07 3.01 2.07
% Diff 0.78 1.13 0.78
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 1,0
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.25: Fifth MapCHECK result for the multitarget IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~The...\MapCHECK_multi-vmat-5(Mancuso,Thesis).txt C:\SNC\Patient Plans\Mancuso~The...\TPS_Map-Multi-VMAT-1mm(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 307
 : 304
 : 3
 : 99
Dose Values in cGy
Cax Normal Picked
Set1 278.09 288.66 278.09
Set2 273.32 279.43 273.32
Set1-Set2 4.77 9.22 4.77
% Diff 1.71 3.30 1.71
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -2,0
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.26: Fifth MapCHECK result for the multitarget VMAT delivery.
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C:\SNC\Patient Plans\Mancuso~Thesi...\MapCHECK_prost-imrt-5(Mancuso,Thesis).txt C:\SNC\Patient Plans\Mancuso~Thes...\TPS_Map-Prost-IMRT-1mm(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 232
 : 229
 : 3
 : 98.7
Dose Values in cGy
Cax Normal Picked
Set1 225.46 232.55 225.46
Set2 224.69 229.22 224.69
Set1-Set2 0.77 3.32 0.77
% Diff 0.34 1.45 0.34
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -4,0
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.27: Fifth MapCHECK result for the prostate IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~The...\MapCHECK_prost-vmat-5(Mancuso,Thesis).txt C:\SNC\Patient Plans\Mancuso~The...\TPS_Map-Prost-VMAT-1mm(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 241
 : 240
 : 1
 : 99.6
Dose Values in cGy
Cax Normal Picked
Set1 222.01 221.19 222.01
Set2 218.03 213.47 218.03
Set1-Set2 3.97 7.72 3.97
% Diff 1.86 3.62 1.86
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -4.5,0.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.28: Fifth MapCHECK result for the prostate VMAT delivery.
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C:\SNC\Patient Plans\Mancuso~Thes...\MapCHECK_neck-imrt-5(Mancuso,Thesis).txt C:\SNC\Patient Plans\Mancuso~The...\TPS_Map-Neck-IMRT-1mm(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 262
 : 257
 : 5
 : 98.1
Dose Values in cGy
Cax Normal Picked
Set1 256.97 345.72 256.97
Set2 266.11 335.23 266.11
Set1-Set2 -9.13 10.48 -9.13
% Diff -2.72 3.13 -2.72
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 1.5,-2.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.29: Fifth MapCHECK result for the head and neck IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~Th...\MapCHECK_neck-vmat-5(Mancuso,Thesis).txt C:\SNC\Patient Plans\Mancuso~The...\TPS_Map-Neck-VMAT-1mm(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 279
 : 274
 : 5
 : 98.2
Dose Values in cGy
Cax Normal Picked
Set1 255.27 310.92 255.27
Set2 265.47 323.00 265.47
Set1-Set2 -10.20 -12.08 -10.20
% Diff -3.16 -3.74 -3.16
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 1,-3
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.30: Fifth MapCHECK result for the head and neck VMAT delivery.
133
C:\SNC\Patient Plans\Mancuso~The...\MapCHECK_ceasy-imrt-5(Mancuso,Thesis).txt C:\SNC\Patient Plans\Mancuso~Th...\TPS_Map-CEasy-IMRT-1mm(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 266
 : 260
 : 6
 : 97.7
Dose Values in cGy
Cax Normal Picked
Set1 51.91 289.02 51.91
Set2 48.66 293.13 48.66
Set1-Set2 3.24 -4.11 3.24
% Diff 1.11 -1.40 1.11
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 3.5,-2.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.31: Fifth MapCHECK result for the C-shape IMRT delivery.
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C:\SNC\Patient Plans\Mancuso~Th...\MapCHECK_ceasy-vmat-5(Mancuso,Thesis).txt C:\SNC\Patient Plans\Mancuso~Th...\TPS_Map-CEasy-VMAT-1mm(Mancuso,Thesis)
Date: 3/4/2011 MapCHECK QA of Dose Distribution                      Hospital Name: Mary Bird Perkins
QA File Parameter Set1 Set2
Set1-Set2
Patient Name  : 
Patient ID  : A10147
Plan Date  : 2011-03-04 
SSD  : 100.0
Depth  : 
Energy  : 0
Angle  : 
Absolute Dose Comparison
% Diff
Distance (mm)
Threshold
Rotation Angle
Meas Uncertainty  : Yes
Dose Diff Thresh  : 0.0 cGy
Summary (Gamma Analysis)
Total Points
Passed
Failed
% Passed
 : 0.0 Degs
 : 3.0
 : 3.0
 : 10.0
 : 281
 : 274
 : 7
 : 97.5
Dose Values in cGy
Cax Normal Picked
Set1 45.50 304.72 45.50
Set2 43.38 293.80 43.38
Set1-Set2 2.12 10.93 2.12
% Diff 0.72 3.72 0.72
DTA(mm) 0.00 0.00 0.00
0,0Coords
(y,x) cm
0,0 -4.5,2.5
Notes
Reviewed By :
Set1 Set2
X ( m m )
1 0 05 00- 5 0- 1 0 0
c
G
y
3 2 0
3 0 0
2 8 0
2 6 0
2 4 0
2 2 0
2 0 0
1 8 0
1 6 0
1 4 0
1 2 0
1 0 0
8 0
6 0
4 0
2 0
0
Figure B.32: Fifth MapCHECK result for the C-shape VMAT delivery.
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of Science degree in physics at Brigham Young University later that year. From 2003 to
2005 he served as a missionary for The Church of Jesus Christ of Latter-day Saints in the
Madagascar Antananarivo mission.
After finishing his undergraduate work at BYU in 2008, he moved to Baton Rouge,
Louisiana, with his wonderful wife Megan, and began working on a master’s degree in
medical physics at Louisiana State University. Following graduation, he will begin a two
year residency program at OncoLogics in Lafayette, Louisiana, where he will be trained
further in clinical medical physics work. He plans to pursue a career in clinical medical
physics. His last name is Italian and means “left-handed.”
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